INVESTIGATING THE LONGITUDINAL PATTERNS OF USE AND COMPARATIVE EFFECTIVENESS OF BETA BLOCKER THERAPY IN THE HEMODIALYSIS POPULATION by Assimon, Magdalene
INVESTIGATING THE LONGITUDINAL PATTERNS OF USE AND COMPARATIVE 




Magdalene Marie Assimon 
 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department 











M. Alan Brookhart 
Jason P. Fine 
Jennifer E. Flythe 
Gerardo Heiss 
























Magdalene Marie Assimon 





Magdalene Marie Assimon: Investigating the longitudinal patterns of use and comparative 
effectiveness of beta blocker therapy in the hemodialysis population 
(Under the direction of M. Alan Brookhart) 
United States hemodialysis patients experience high rates of cardiovascular mortality. 
Approximately 50% of deaths are due to cardiovascular disease. In the general population, beta 
blocker treatment improves clinical outcomes in a range of cardiovascular conditions. However, 
the cardioprotective benefit of beta blocker therapy has never been evaluated by large randomized 
trials in individuals receiving maintenance hemodialysis therapy, a population with special drug 
dosing considerations. Pharmacologic and pharmacokinetic differences across individual beta 
blockers may alter drug efficacy and safety profiles in the setting of end-stage renal disease. Using 
the clinical research database of a large United States dialysis provider linked with the United 
States Renal Data system registry we assembled a cohort of maintenance hemodialysis with 
Medicare insurance coverage who initiated beta blocker therapy from 2007 – 2012 to: 1) assess 
long-term beta blocker utilization patterns in the hemodialysis population, 2) examine the 
association between beta blocker adherence versus non-adherence (proportion of days covered 
(PDC)  ≥ 80% versus PDC < 80%) and all-cause mortality, and 3) evaluate the association between 
carvedilol versus metoprolol initiation and 1-year all-cause and cardiovascular mortality.  
First, we found that carvedilol and metoprolol were the most commonly initiated beta 
blockers (79.7% of all beta blocker new-users). After beta blocker initiation, therapy cessation (i.e. 
discontinuation) and re-initiation were relatively common. Second, we found that beta blocker 
adherence (versus non-adherence) was associated with lower all-cause mortality (PDC ≥ 80% 
iv 
 
versus < 80% measured using pharmacy claims: adjusted hazard ratio (HR) [95% confidence 
interval (CI)] = 0.84 [0.79, 0.90]). Finally, we found that carvedilol (versus metoprolol) initiation 
was associated with higher all-cause (adjusted HR [95% CI] = 1.09 [1.02, 1.16]) and 
cardiovascular mortality (adjusted HR [95% CI] = 1.19 [1.08, 1.30]). The potential mechanism for 
the observed mortality association may be the increased rate of intradialytic hypotension observed 
after carvedilol (versus metoprolol) initiation.  
Our findings provide insights into: 1) the longitudinal patterns of beta blocker utilization 
among individuals receiving maintenance hemodialysis therapy, 2) the association between beta 
blocker adherence and all-cause mortality, and most importantly, 3) provide important evidence 
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CHAPTER 1: SPECIFIC AIMS 
United States (U.S.) hemodialysis patients experience exceedingly high rates of 
cardiovascular mortality, nearly 50% of deaths are attributed to cardiovascular causes. In the 
general population, pharmaceutical interventions such as beta blockers improve clinical outcomes 
among individuals with hypertension, heart failure, atrial fibrillation and post-myocardial 
infarction. The cardioprotective benefit of beta blocker therapy has never been evaluated in large 
randomized trials among hemodialysis patients, a population with unique pharmacokinetic and 
hemodynamic considerations. Pharmacologic and pharmacokinetic differences across individual 
beta blockers may alter drug efficacy and safety profiles in the setting of end-stage renal disease 
(ESRD). Despite this evidence void, over 60% of hemodialysis patients receive beta blockers. A 
clear understanding of the longitudinal patterns of beta blocker use in a real-world setting 
combined with a rigorous assessment of the comparative effectiveness of the most commonly used 
beta blockers in the U.S. is urgently needed to improve clinical decision making and to guide beta 
blocker prescribing in the hemodialysis population. Using the clinical research database of a large 
U.S. large dialysis provider linked with the U.S. Renal Data System (USRDS), the following 
specific aims were addressed in this dissertation. 
 
Aim 1: An investigation of the long-term beta blocker utilization patterns in the hemodialysis 
population to: 
1A. Characterize and describe beta blocker initiators by beta blocker subtype (e.g. non-
selective, cardioselective, and alpha beta blockers) and individual generic products.  
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1B. Estimate the cumulative incidence of beta blocker discontinuation and switching after 
initiation: 
- Overall (among all beta blocker initiators). 
- Among carvedilol and metoprolol initiators (separately). 
1C. Estimate the cumulative incidence of beta blocker re-initiation after beta blocker 
discontinuation: 
- Overall (among all beta blocker discontinuers). 
- Among carvedilol and metoprolol discontinuers (separately). 
 
Aim 2: To examine the association between beta blocker adherence (proportion of days covered 
≥ 80%) versus non-adherence (proportion of days covered < 80%) and all-cause mortality when:  
2A. The proportion of days covered is computed using standard methods (i.e. using 
administrative pharmacy claims only). 
2B. The proportion of days covered is computed using modified methods (i.e. using 
administrative pharmacy claims and also accounting for time periods when patients were 
admitted to the hospital or a skilled nursing facility using inpatient/outpatient claims). 
 
Aim 3: To evaluate the association between carvedilol versus metoprolol initiation and 1-year all-
cause and cardiovascular mortality, overall and within clinically relevant subgroups (including 








CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
The public health importance of reducing cardiovascular risk among hemodialysis patients 
and the potential role of beta blocker therapy  
Hemodialysis patients possess a tremendous cardiovascular disease burden, which 
contributes to unacceptably poor outcomes. Compared to individuals without kidney disease, 
cardiovascular mortality rates are 5 to 7-fold higher among individuals receiving maintenance 
hemodialysis.1 Cardioprotective medications such as beta blockers, among others, are often 
prescribed as a means to reduce cardiovascular risk across several conditions (e.g. hypertension, 
atrial fibrillation, heart failure and post-myocardial infarction). However, clinical trials 
establishing the cardioprotective nature and safety of beta blocker therapy largely excluded 
hemodialysis patients,2, 3 a population with special drug dosing considerations.  
Currently, due to a lack of population-specific evidence,4 clinicians are forced to apply beta 
blocker clinical trial data that was generated in non-dialysis patient cohorts to those receiving 
maintenance hemodialysis. Pharmacologic and pharmacokinetic differences across individual beta 
blockers may alter medication safety and efficacy profiles in the setting of ESRD. 
Pharmacologically, beta blockers differ with respect to their beta-adrenergic receptor selectivity 
and vasodilatory capabilities. Kinetically, physiochemical factors, such as molecular size, 
hydrophilicity, plasma protein binding, and the volume of distribution influence the extent of beta 
blocker clearance by the hemodialysis procedure (i.e. dialyzablity). These key differences may 
plausibly alter the hemodynamic and antiarrhythmic risk-benefit profiles of individual beta 





hemodialysis population, understanding the comparative safety and effectiveness of individual 
beta blocker medications is essential for determining optimal cardiovascular treatment strategies 
in this vulnerable patient group.  
Brief overview of beta blocker pharmacology 
Beta blockers (also termed beta-adrenergic blocking agents, beta-antagonists, beta-
adrenergic antagonists, beta-adrenoreceptor antagonists or beta-adrenergic receptor antagonists) 
are a class of drugs that are commonly used in the management of cardiovascular disorders. There 
are 3 main subclasses of beta blocker medications including non-selective beta blockers 
(propranolol, pindolol, nadolol, sotalol, timolol), cardioselective beta blockers (acebutolol, 
atenolol, betexolol, bisoprolol, metoprolol, nebivolol) and alpha-beta blockers (carvedilol, 
labetalol). Cardioselective and alpha-beta blockers are the beta blocker subtypes most commonly 
prescribed to hemodialysis patients. Metoprolol (tartrate and succinate), a cardioselective beta 
blocker, and carvedilol, an alpha-beta blocker carvedilol, account for nearly 80% beta blocker 
prescriptions the U.S. dialysis population.5 Thus, the remainder of this chapter will often highlight 
metoprolol and carvedilol. 
Beta blocker medications are competitive antagonists. Competitive antagonists are drug 
molecules that bind to specific target receptors located in the body and have no subsequent biologic 
effect (i.e. they do not activate the target receptors). Antagonistic medications compete with 
available agonist molecules (endogenous proteins or hormones that bind to and activate target 
receptors resulting in a subsequent biologic effect) for binding sites on target receptors.  When a 
sufficient concentration of an antagonist is systemically available, it will displace the agonist from 
receptor binding sites, resulting in a lower frequency of target receptor activation and effectively 





Not surprisingly, the various beta blocker medications possess different pharmacologic 
properties. Once in systemic circulation, these medications compete with catecholamines (e.g. 
epinephrine and norepinephrine) for binding at target receptors located in several tissues 
throughout the body. Metoprolol is a cardioselective beta blocker. Metoprolol acts mainly on the 
heart, with a high specificity for the beta-1 adrenergic receptor. In contrast, carvedilol is an alpha-
beta blocker. Carvedilol acts on the heart, vasculature and other tissues, blocking beta-1, beta-2 
and alpha-1 adrenergic receptors. Both medications reduce heart rate and cardiac contractility by 
blocking beta-1 receptors in the sinoatrial node and myocardium. In contrast, carvedilol has 
additional vasodilatory effects due to its antagonistic action on alpha-1 receptors located in blood 
vessels. Furthermore, carvedilol has some activity at beta-2 receptors located in the lungs, liver 
and pancreas, which may lead to the occurrence of side effects such as bronchoconstriction (due 
to the antagonistic effect of carvedilol on the lungs) increases in serum glucose (due to the 
antagonistic effects of carvedilol on the liver and pancreas) and hyperkalemia (due to its 
antagonistic effects on beta-2-receptors, carvedilol may impair the epinephrine-mediated the 
movement of extracellular potassium into the cells). 
Brief overview of beta blocker pharmacokinetics 
Pharmacokinetics is the quantitative description of drug disposition in the human body, 
including drug absorption, distribution, metabolism and elimination. Hemodialysis may affect 
drug pharmacokinetics, and in some cases drug dosing adjustments are required. The need for a 
dosage adjustment arises when a significant fraction of the drug or its active metabolites are cleared 
from systemic circulation by the hemodialysis procedure (termed drug dialyzablity). In such cases, 
a change in the dosing regimen, such as the administration of supplemental doses following the 





factors, such as molecular weight, hydrophilicity, plasma protein-binding, and the volume of drug 
distribution, in the body are key medication properties which determine a medications’s level of 
dialyzablity. 
Individual medications within the beta blocker class display considerable pharmacokinetic 
heterogeneity, differing with regards to half-life, hydrophilicity, plasma protein-binding, volume 
of distribution, sites of metabolism, and route of elimination. A striking pharmacokinetic 
difference between these medications is their route of elimination. The main route of elimination 
of metoprolol (tartrate and succinate) and its corresponding metabolites is renal excretion (5 to10% 
as unchanged drug), whereas carvedilol and its metabolites are primarily excreted in the feces.6-8 
In addition, due to their physiochemical characteristics (Table 2.1),6-8 metoprolol is highly 
dialyzable and carvedilol is minimally dialyzable (comparing metoprolol to carvedilol, 
hemodialytic clearance: 148 versus 18 mL/min; fraction of elimination due to hemodialysis: 13% 
versus 4%).9 
 
Brief overview of the beneficial cardiovascular effects of beta blocker therapy in 
hypertension, heart failure, atrial fibrillation, and post-myocardial infarction  
Despite the fact that approximately half of all deaths in the hemodialysis population are 
due to cardiovascular disease, evidence guiding the treatment of cardiovascular conditions in 
ESRD is non-existent. Treatment protocols and regimens must be extrapolated from the general 
population evidence-base. According to current cardiovascular guidelines, beta blocker therapy is 
indicated and should be initiated after a myocardial infarction,10, 11 and among patients with heart 
failure or left ventricular dysfunction.12 In addition, beta blockers are also given to control heart 





of other non-cardiovascular disorders such as migraines and anxiety. Even though beta blockers 
have anti-hypertensive effects, in the absence of the prior aforementioned cardiovascular 
indications, they are not recommend as first-line therapy in the treatment of essential hypertension, 
particularly in patients over 60 years of age.13-15 Atrial fibrillation, heart failure, and coronary 
artery disease are common in the U.S. hemodialysis population, with a prevalence of 
approximately 35%, 40%, and 10% respectively.16-18 Thus, the beneficial effects of beta blocker 
therapy in the setting of atrial fibrillation, heart failure and myocardial infraction (a sequelae of 
coronary artery disease) are reviewed below.  
Atrial fibrillation 
Atrial fibrillation is an abnormal heart rhythm characterized by the loss of the regular and 
organized contraction of the left atrium and a subsequent increase in ventricular rate. In the typical 
patient with untreated atrial fibrillation, the ventricular rate can reach 150 beats/minute or higher 
(normal resting heart rate = 60 to 100 beats/minute), often leading to the occurrence symptoms 
that impair both functional status and quality of life such as heart palpitations, weakness, fatigue, 
lightheadedness, dizziness, confusion, and shortness of breath. In addition to providing patients 
with anticoagulation as a means to prevent thromboembolism, a major goal of atrial fibrillation 
management is to mitigate symptoms using either a rate-control strategy (e.g. treatment with a 
chronotropic medication to reduce heart rate) or a rhythm control strategy (e.g. treatment with an 
anti-arrhythmic drug to maintain sinus rhythm after cardioversion).19 Oral beta blockers are widely 
used as primary therapy for rate control in chronic atrial fibrillation. These medications block the 
activity of catecholamines (e.g. epinephrine, norepinephrine) at beta-1 receptors in the sinoatrial 
node of the heart, subsequently slowing cardiac conduction through the atrioventricular node. This 







Heart failure is a progressive clinical syndrome resulting from changes in cardiac structure 
and/or function that inhibits the ability of ventricles to fill with or eject blood. Heart failure can be 
due to abnormalities in systolic function, diastolic function, or both. The majority of heart failure 
present in individuals receiving maintenance hemodialysis is due to systolic dysfunction (also 
known as heart failure with reduced ejection fraction). Population-based estimates vary, but 
indicate that 35 to 70% of hemodialysis patients have left ventricular hypertrophy.20, 21  In the 
general heart failure population with systolic dysfunction, clinical trials have shown that treatment 
with beta blockers slows heart failure progression and improves survival.22 This general population 
evidence is supported by a small randomized trial conducted in hemodialysis patients with dilated 
cardiomyopathy, which demonstrated that treatment with the alpha-beta blocker carvedilol (versus 
placebo) reduced mortality.23  
In heart failure, chronic stimulation of cardiac beta receptors, caused by increased 
sympathetic activity, leads to progressive worsening of ventricular function, as well as systemic 
and pulmonary vasoconstriction. Beta blocker administration upregulates myocardial beta-1 
receptor density in patients with heart failure, helping to restore the inotropic and chronotropic 
responsiveness of the myocardium. This subsequently results in heart rate reduction and an 
improvement in cardiac contractile function.24, 25 In addition, beta blockers reduce the circulating 
level of vasoconstrictors, renin and endothelin. The corresponding vasodilatory effect leads to a 
decrease in cardiac afterload, thereby reducing the rate of ventricular hypertrophy and the 
development of cardiac dysfunction.25 
Post-myocardial infarction 
An acute myocardial infarction, or heart attack, is clinical or pathologic myocardial 





an unstable atherosclerotic plaque stimulates the formation of an intracoronary thrombus that 
occludes coronary artery blood flow. This obstruction leads to the death of myocardial tissue 
downstream of the blockage. Based upon clinical trials conducted in the general population, it is 
well established that treatment with a beta blocker among acute myocardial infarction patients 
reduces infarct size and the risk of early death, and also lowers the risk of mortality when therapy 
is continued long term.26  
The beneficial effects of beta blocker therapy among myocardial infraction patients result 
from the antagonism of beta-1 receptors on the heart. These physiologic benefits include: 
decreased cardiac oxygen demand due to beta blocker induced reductions in heart rate, blood 
pressure, and cardiac contractility; reduction in cardiac remodeling and improvement in left 
ventricular hemodynamic function; improved left ventricular diastolic function with a less 
restrictive filling pattern; an increased ventricular fibrillation threshold, lowering the risk of sudden 
cardiac death; and inhibition of platelet aggregation and thromboxane synthesis.27 
Beta blocker utilization in the hemodialysis population 
Roughly 60% of U.S. hemodialysis patients use beta blocker medications.28 A clear and 
detailed understanding of the patterns of beta blocker utilization is critical prior to designing 
comparative effectiveness/safety studies, since the occurrence of clinical outcomes and adverse 
events are often contingent on longitudinal drug exposure (i.e. time on therapy, and current therapy 
utilization). Thus, a well-designed, comprehensive patterns of use study, describing longitudinal 
beta blocker utilization (beta blocker discontinuation, switching and re-initiation post-
discontinuation), is needed. Currently, the existing evidence-base is weak.5, 28-41 The majority of 
epidemiologic studies evaluating beta blocker utilization among individuals receiving 





investigations evaluated the beta blocker class as a whole, and provide limited, if any, information 
on utilization patterns of beta blocker subclasses or individual agents. The major findings of the 
most contemporary, large-scale observational studies of beta blocker utilization among 
hemodialysis patients are summarized below. 
Using data from the USRDS, Frankenfield et al. described the use of cardiovascular drugs 
in 225,635 hemodialysis and peritoneal dialysis patients with continuous Medicare Part D 
coverage during 2007.28 Beta blockers were the most commonly used cardiovascular medication 
class with 64% of study patients filling at least 1 beta blocker prescription during the study period. 
Among patients with hypertension, atrial fibrillation and a history of a prior myocardial infarction 
myocardial infraction, beta blocker utilization was highly prevalent. A total of 74%, 69% and 79% 
of study patients with the respective cardiovascular comorbidities used a beta blocker. Similarly, 
an investigation using dialysis unit medical record data revealed that beta blocker therapy was 
commonly used by hemodialysis patients. Specifically, St. Peter et al. aimed to describe the 
patterns of blood pressure medication use among 12,159 incident hemodialysis patients treated at 
a large U.S. dialysis organization (Dialysis Clinic Incorporated) between 2003 and 2008.5 In this 
cohort, 60% of patients were using a beta blocker at 6 months after starting dialysis, with 41% of 
patients using either a cardioselective or non-selective beta blocker and 19% of patients using an 
alpha-beta blocker. Metoprolol (53% of patients) and carvedilol (25% of patients) were the most 
commonly used agents.  
While the data documenting the prevalence of beta blocker utilization has been well 
described in both small dialysis clinic-based studies and large-scale cross-sectional hemodialysis 
patient cohorts,5, 28-40 data characterizing the longitudinal use of these medications across time is 





eligible for Medicaid and Medicare insurance from the years 2000 to 2005, Wetmore et al. used 
the proportion of days covered (PDC) metric to describe long-term use of anti-hypertensive 
medications including beta blockers.42 The maximum study follow-up time was 5 years. 
Additionally, both prevalent and new beta blocker users were included in this cohort. The PDC 
was computed as follows: (the number of days a patient had a medication of interest available 
during follow-up) / (the patient’s total number of follow-up days) x 100%. A total of 24,818 study 
patients used beta blocker therapy and were considered in descriptive PDC analyses. The authors 
found that on average, individuals had beta blocker therapy available for a mean ± standard 
deviation of 53% ± 31% of days during study follow-up. Differences in proportion of days covered 
by beta blocker subclass or across individual beta blocker medications (e.g. metoprolol or 
carvedilol) were not evaluated. While this investigation was the first to describe beta blocker use 
across time among dialysis patients, it only provides a crude measure of long-term beta blocker 
utilization patterns. The PDC is a simple metric that describes the percentage days during follow-
up each patient had drug available. We are not able to discern more precise patterns of medication 
utilization, for instance if a patient discontinued beta blocker therapy completely or if the patient 
was intermittently using beta blockers across time. Recently, there has been increased interest in 
evaluating the association between longitudinal cardiovascular medication adherence (measured 
using PDC) and all-cause mortality among individuals with kidney disease.43 However, PDC 
calculation methods, which rely on outpatient prescription pharmacy claims, likely require special 
computational considerations in the in the hemodialysis population. In particular, time periods 
spent in the hospital or a skilled nursing facility, where medications are provided to patients by the 
institutional pharmacies and prescription drug benefit-derived home medication supplies are not 





Beta blocker therapy and clinical outcomes in the hemodialysis population 
Randomized controlled trials 
Existing randomized controlled trial data assessing the association between beta blocker 
therapy and hard clinical outcomes is limited to 3 small studies. First, in a study of 114 Neapolitan 
hemodialysis patients with dilated cardiomyopathy and an ejection fraction ≤ 35%, participants 
were randomized to receive either the alpha-beta blocker carvedilol or placebo.23 After 2 years of 
treatment, those treated with carvedilol had smaller heart chamber diameters and a higher ejection 
fraction compared placebo group, suggesting an attenuation of cardiac remodeling with carvedilol. 
These findings were accompanied by a survival advantage, demonstrating that treatment with 
carvedilol lowered both all-cause, hazard ratio (HR) [95% confidence interval (CI)] = 0.51 [0.32, 
0.82], and cardiovascular mortality, HR [95% CI] = 0.32 [0.18, 0.57]. In addition, time to first 
hospitalization was lower among patients receiving carvedilol, HR [95% CI] = 0.44 [0.25, 0.77]. 
Second, in a study of 200 American hemodialysis patients with hypertension and left ventricular 
hypertrophy, participants were randomized to receive the cardioselecive beta blocker atenolol 
(dosed three times a week on after hemodialysis treatments) or the angiotensin converting enzyme 
inhibitor lisinopril (dosed daily)44 The primary outcome for this study was change in left 
ventricular mass index at 12 months. However, this trial was terminated early because of a 
cardiovascular safety issue. The occurrence of the composite cardiovascular safety outcome 
(myocardial infarction, stroke, hospitalization for heart failure or cardiovascular death) was higher 
in the lisinopril group as compared to the atenolol group, incidence rate ratio (IRR) [95% CI] = 
2.29 [1.07, 5.21]. In addition, the incidence rate of all-cause hospitalizations was higher in the 
lisinopril group as compared to the atenolol group, IRR [95% CI] = 1.61 [1.18, 2.19]. The results 





to lisinopril-based anti-hypertensive therapy for preventing cardiovascular morbidity and all-cause 
hospitalizations. Finally, the Beta Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) 
Study was a pilot investigation designed to assess the feasibility of conducting a randomized 
controlled trial evaluating the effect treating patients with the alpha-beta blocker carvedilol or 
placebo on all-cause mortality among hemodialysis patients.45 The target enrollment for this study 
was 150 hemodialysis patients. A total of 1,443 hemodialysis patients across 11 dialysis units in 
Australia and New Zealand were screened for study eligibility. Three hundred and fifty-four 
patients (354) were met study eligibility criteria, and of these individuals 91 patients consented to 
participate in the study and 74 patients were enrolled (i.e. started the initial run-in phase). During 
a 6-week run-in phase, all study patients were treated with carvedilol. After completing the run-in 
phase, participants were randomized to treatment with either carvedilol or placebo and followed 
for 12 months. Of the 72 patients that entered the run-in phase, only 49 patients went on to enter 
the randomization phase. A total of 5 patients (7%) withdrew from the trial during the run-in phase 
due to the occurrence of severe bradycardia or hypotension, established adverse side effects of 
carvedilol therapy. In randomization phase, participants treated with carvedilol had a higher, but 
statistically insignificant, rate of intradialytic hypotension (i.e. low blood pressure during 
hemodialysis defined as a decrease in systolic blood pressure ≥ 20 mmHg accompanied by 
hypotensive symptoms that required treatment) versus those receiving placebo (7 versus 2 
events/100 hemodialysis treatments, p = 0.1). The results of this feasibility trial suggest that: 1) 
recruiting a large number of hemodialysis into a randomized controlled trial of beta blocker therapy 
(versus placebo) will be challenging; and 2) beta blocker tolerability may impact therapy 






Observational studies evaluating the beta blocker use—mortality association 
Observational studies examining the relationship between beta blocker therapy and 
mortality in the hemodialysis population have mainly focused on comparing beta blocker users to 
non-users. For the most part, existing epidemiologic evidence (Table 2.2) suggests that beta 
blocker therapy, as a class, may reduce all-cause and cardiovascular mortality. However, the 
results of these studies should be interpreted with their limitations in mind. First, employment of 
a prevalent user design will miss outcome events that occur early in follow-up (i.e. events 
occurring right after beta blocker initiation). Second, use of a non-beta blocker comparator group 
could generate biased effect estimates due to the presence of substantial residual confounding by 
indication. Beta blocker non-users are likely different from patients randomized to placebo. Non-
users may not have a medical indication for beta blocker therapy, they may have used beta blockers 
in the past and stopped due to a side effect, or they may have contraindications to the beta blocker 
therapy. Finally, a common scenario nephrology providers face when prescribing beta blockers is 
deciding which beta blocker they should treat their hemodialysis patients with, rather than deciding 
if they should treat their patient with a beta blocker versus no therapy. Thus, data from comparative 
studies that evaluated beta blocker use versus non-use may be of limited clinical utility.  
Additional research on the comparative effectiveness/safety of beta blockers in the 
hemodialysis population is needed 
Existing observational evidence suggests that the potential survival benefit conferred by 
beta blockers may differ across agents. To date, only two observational studies have considered 
head-to-head beta blocker comparisons. Weir et al. assessed the association between beta blocker 
dialyzability and 180-day mortality in a cohort of 6,588 elderly (>66 years of age), hemodialysis 





Initiation of a highly dialyzable beta blocker (acebutolol, atenolol, metoprolol tartrate) versus a 
minimally dialyzable beta blocker (bisoprolol and propranolol) was significantly associated with 
higher all-cause mortality, adjusted odds ratio [95% CI] = 1.4 [1.1, 1.8]. This study provided initial 
evidence that beta blocker heterogeneity may differentially impact clinical outcomes in the 
hemodialysis population. However, carvedilol and metoprolol succinate, which account for 
approximately 50% of all beta blocker prescriptions in the U.S.5 were not considered in this study 
due to provincial prescription formulary restrictions limiting their use. Metoprolol (tartrate and 
succinate) is a cardioselective beta blocker and is extensively cleared by hemodialysis. Carvedilol 
is a non-selective beta blocker with additional alpha-blocking effects and is minimally cleared by 
hemodialysis.   
In another observational study, Shireman et al. evaluated the association between beta 
blocker selectivity and mortality in a cohort of 4,398 incident U.S. hemodialysis and peritoneal 
dialysis patients with dual Medicare/Medicaid coverage and hypertension.47 Initiation of a 
cardioselective beta blocker (atenolol, metoprolol) versus a non-selective beta blocker (carvedilol, 
labetalol) was associated with lower 5-year all-cause mortality, adjusted HR [99% CI] = 0.84 
[0.72, 0.97]. However, the relative contributions of carvedilol and metoprolol, the most commonly 
beta blockers prescribed to individuals receiving maintenance dialysis in the U.S., to the observed 
association are unclear. Furthermore, this investigation relied on data from 2000 to 2005, prior to 
the introduction of the Medicare Part D prescription drug benefit, and also used a study population 
comprised of patients new to dialysis therapy with dual Medicare and Medicaid insurance 
coverage. Currently, prevalent dialysis patients (individuals with a dialysis vintage > 1 year) 
comprise roughly 60 to 70% the ESRD population, and the vast majority of individuals receiving 





that a contemporary analysis evaluating the association between beta blocker initiation and clinical 
outcomes in a representative patient cohort is needed.  
While a head-to-head randomized clinical trial would be the ideal approach to investigating 
the comparative safety and efficacy of individual beta blockers in the dialysis population, recent 
data from the BLOCADE feasibility study suggested that recruitment for such a trial may be 
challenging.45 Well-designed pharmacoepidemiologic studies are thus needed to inform clinical 
decision-making. A hallmark feature of a well-designed comparative effectiveness/safety study is 
that the medications being compared to one another represent clinically meaningful treatment 
choices. Real-world treatment decisions are based on numerous factors a such as the severity of 
the underlying disease-state, as well as patients’ general health status and patient preferences. 
Confounding by indication can be minimized by choosing to evaluate medications with the same 
(or very similar) indications, contraindications, and routes of administration. A notable limitation 
of the studies by Weir et al. and Shireman et al. is that the beta blockers studied have different 
therapeutic roles in the setting of contemporary clinical nephrology practice. The beta blocker 
medications that were contrasted may not represent exchangeable treatment alternatives, and thus 
indication bias may have influenced the results. For instance, in the case of the Weir study, the 
Food and Drug Administration (FDA) labeled indications of the highly dialyzable beta blocker 
metoprolol include angina, heart failure, hypertension, and post-myocardial infarction,6, 7 whereas 
the only FDA labeled indication for the minimally dialyzable bisoprolol is hypertension.49 
Similarly, in the Shireman study, the cardioselective beta blocker metoprolol has a greater number 
of cardiovascular indications (previously mentioned) as compared to the to the non-selective beta 
blocker labetalol (hypertension is in the only FDA labeled indication of this medication).50 Given 





initiation of the most commonly used beta blockers with similar indication profiles (metoprolol 
and carvedilol) and mortality is needed to inform cardiovascular clinical decision making in the 
U.S. hemodialysis population. 
 
The differential pharmacologic and pharmacokinetic profiles of carvedilol and metoprolol 
may impact the cardioprotective nature of these medications in the unique end-stage renal 
disease environment 
Clinical evidence from the general population suggests that the relative efficacy of 
individual beta blockers may differ across cardiovascular disease states.51-56 Meta-analyses of 
randomized controlled trials indicate that treatment with the vasodilating beta blocker carvedilol 
may improve left ventricular function and survival to a greater extent than the cardioselective beta 
blocker metoprolol in the general, non-dialysis heart failure population.51, 52 Even though the 
findings from this meta-analysis suggest treatment with carvedilol (versus metoprolol) may result 
in better clinical outcomes in heart failure, these benefits may not translate to individuals receiving 
maintenance dialysis. Specific to the hemodialysis population, the marked pharmacologic and 
pharmacokinetic heterogeneity between metoprolol carvedilol in combination with the unique 
ESRD environment (i.e. exposure to frequent hemodynamic and electrolyte shifts), may alter the 
risk-benefit profiles of these medications. Thus, we cannot rely on general population beta blocker 
data to guide prescribing practices when treating individuals receiving maintenance hemodialysis.  
Although carvedilol and metoprolol are both beta blockers, their pharmacologic sites of 
action differ. As previously described, metoprolol (tartrate and succinate) is a cardioselective beta 
blocker (blocks beta-1 adrenergic receptors), whereas carvedilol is a non-selective beta blocker 





(blocks alpha-1 adrenergic receptors). Due to their action on the cardiac-based beta-1 receptor, 
both metoprolol and carvedilol reduce heart rate and cardiac contractility. Since carvedilol also 
has activity at the alpha-1 receptor, it is a peripheral vasodilator. Precipitous drops in blood 
pressure (i.e. episodes of intradialytic hypotension) during the hemodialysis procedure are 
common, occurring in approximately 10 to 70% of treatments (depending on the definition).57 
Mechanistic studies indicate that hemodynamic compromise during the hemodialysis treatment 
results in the hypoperfusion of vital vascular beds, leading to ischemic damage to the heart58, 59 
and other major organs.60-62 Over time, repeat episodes of hypotension-induced cardiac ischemia 
will result in cardiac hypertrophy and fibrosis and corresponding downstream adverse cardiac 
effects, including heart failure, arrhythmia, and ultimately death.  In fact, the occurrence of more 
frequent intradialytic hypotension has been associated with increased all-cause and cardiovascular 
mortality.57, 63, 64 The vasodilatory properties of carvedilol may influence intradialytic blood 
pressure and thus hemodynamic stability. It is possible that carvedilol-induced alpha-1 blockade 
may blunt compensatory sympathetic nervous system-mediated peripheral vasoconstriction during 
ultrafiltration, increasing the likelihood that intradialytic hypotension will occur.  
Carvedilol also has the potential to impact serum electrolyte concentrations. Antagonism 
of the beta-2 receptor inhibits movement of extracellular potassium into cells. Administration of 
carvedilol, a beta blocker with beta-2 activity, may increase serum potassium levels and the 
associated arrhythmia risk. Pre-dialysis hyperkalemia is common, making hemodialysis patients 
particularly vulnerable to the potassium-raising effect of beta-2 blockade. Carvedilol-induced 
hyperkalemia has been reported in patients with kidney disease.65  
In addition to the potential adverse pharmacologic-related effects, differences in carvedilol 





metoprolol is extensively cleared by hemodialysis and carvedilol is minimally cleared by 
hemodialysis. Acutely, the rapid removal of metoprolol from systemic circulation during the 
hemodialysis may put patients at an increased risk for the occurrence ventricular arrhythmias and 
sudden death. In the long-term, the repeated removal of metoprolol during hemodialysis treatments 
(i.e. on an every-other day basis) may diminish its beneficial cardioprotective effects 
longitudinally. On the other hand, since carvedilol is not readily dialyzable it is possible that 
carvedilol’s antihypertensive effects are maintained during hemodialysis treatments, possibly 





















Table 2.1 Physiochemical properties of metoprolol and carvedilol that impact their 
dialyzablity 
Property Metoprolol tartrate Metoprolol succinate Carvedilol 
Molecular weight 684.8 Daltons 652.8 Daltons 406.5 Daltons 
Hydrophilic No (moderately lipophilic) No (moderately lipophilic) No (highly lipophilic) 
Plasma protein binding 
~12% bound to plasma 
proteins (mainly albumin) 
~12% bound to plasma 
proteins (mainly albumin) 
> 98% bound to plasma 
proteins (mainly albumin) 























Table 2.2 Observational studies assessing beta blocker use versus non-use and mortality  
Author (Year) Study type Population Main findingsa 
    
Foley (2002)16 Cohort study 11,142 hemodialysis patients followed in the USRDS 
Dialysis Morbidity and Mortality Waves 3 and 4 Study 
receiving dialysis on 12/31/1993  
Baseline beta blocker use versus non-use was associated 
with  all-cause mortality  
- HR (95% CI) = 0.84 (0.75, 0.93) 
 
Griffith (2003)66 Cohort study 2,877 incident hemodialysis and peritoneal dialysis 
patients enrolled in the USRDS Morbidity and Mortality 
Study Wave 2 study in 1996 and who were on anti-
hypertensive therapy  
Baseline beta blocker use versus non-use was not 
significantly associated with all-cause and CV mortality 
- All-cause death: HR (95% CI) = 0.94 (0.84, 1.06) 
- CV death: HR (95% CI) = 1.05 (0.89, 1.25) 
 
Berger (2003)67 Cohort study 1,025 ESRD patients treated with hemodialysis or 
peritoneal dialysis who hospitalized for an acute 
myocardial infraction and were enrolled in both the 
USRDS and the Cooperative Cardiovascular Project 
Beta blocker administration during hospitalization for 
acute MI versus no beta blocker treatment was associated 
with  30 day all-cause mortality 
- OR (95% CI) = 0.78 (0.60, 0.99) 
 
Chow (2003)36 Cohort study 262 hemodialysis and peritoneal dialysis patients 
receiving dialysis at Monash Medical Center (Australia) 
on 05/31/1996 
Baseline beta blocker use versus non-use was not 
associated with all-cause mortality 
- The corresponding HR was not presented 
 
Abbott (2004)68 Cohort study 2,250 incident hemodialysis and peritoneal dialysis 
patients enrolled in the USRDS Morbidity and Mortality 
Study Wave 2 study who were Medicare eligible at study 
enrollment in 1996 
Baseline beta blocker use versus non-use was associated 
with   occurrence of the a composite end-point of CV 
death or hospitalized heart failure 
- HR (95% CI) = 0.77 (0.61, 0.97) 
 
Ishani (2004)69 Cohort study 3,044 incident hemodialysis or peritoneal dialysis 
patients enrolled in the USRDS Morbidity and Mortality 
Study Wave 2 study who were Medicare eligible at study 
enrollment in 1996 and 1997 
Baseline beta blocker use versus non-use was not 
significantly associated with the composite outcome of 
all-cause death or a CV event (MI, stroke, heart failure or 
PVD) 
- HR (95% CI) = 0.95 (0.85, 1.06) 
 
Winkelmayer (2006)70 Cohort study 902 elderly dialysis patients hospitalized for MI who 
survived 90 days after discharge and who were enrolled 
in Medicare, and PAAD or PACE 
Beta blocker use versus non-use during the first 90 days 
after discharge for acute MI was not associated with all-
cause death 
- HR (95% CI) = 1.05 (0.78, 1.43) 
 
Pun (2007)71 Nested case-control study 729 hemodialysis patients treated at a Gambro Facility 
between 2002 to 2005 who experienced cardiac arrest  
Beta blocker use versus non-use at the time of cardiac 
arrest was associated with  all-cause death after cardiac 
arrest 
- OR (95% CI) =  0.32 (0.17, 0.61)  
 
Lopes (2009)29 Cohort study 17,350 hemodialysis patients enrolled in DOPPS I and II 
 
Baseline beta blocker use versus non-use was associated 







- HR = 0.87 (95% CI were not presented) 
 
Nakao (2009)72 Cohort study 2,286 hemodialysis patients enrolled in DOPPS II from 
Japan 
Baseline beta blocker use versus non-use was associated 
with  all-cause mortality 
- HR (95% CI) = 0.48 (0.25, 0.88) 
 
Tangri (2011)73 Cohort study 1,747 hemodialysis patients enrolled in the HEMO Study Baseline beta blocker use versus non-use was not 
significantly associated with sudden cardiac death among 
those with and without ischemic heart disease 
- With: HR (95% CI) = 0.65 (0.42-1.01) 
- Without: HR (95% CI) = 1.61 (0.92-2.80) 
 
Kitchlu (2012)74 Cohort study 1,836 elderly, incident hemodialysis patients from 
Ontario, Canada who initiated maintenance dialysis 
therapy between 07/1991 and 07/2007 who were new 
users of a study drug of interest  
- Defined as filling least 2 prescriptions for a beta 
blocker, calcium channel blocker or a statin between 60 
to 120 days apart 
New beta blocker use versus new statin use was not 
associated with all-cause mortality 
- HR (95% CI) = 1.07 (0.92, 1.23) 
 
New use of a high dose beta blocker versus a low dose 
was associated with  all cause mortality 
- HR (95% CI) = 0.50 (0.29, 0.88) 
 
Matsue (2013)75 Cohort study 306 hemodialysis patients treated at Kameda Medical 
Center (Japan) from 2005 - 2006 
Baseline beta blocker use versus non-use was associated 
with  sudden cardiac death  
- HR (95%) = 0.21 (0.06, 0.69) 
 
Tang (2015)76 Ecologic study 50,468 incident hemodialysis patients dually eligible for 
Medicare and Medicaid from 2000 – 2005 
Zip codes with a higher than expected use of beta 
blockers (area treatment ratio > 1) versus those with lower 
than expected use had  rates of all-cause mortality 
- β = -0.161, p = 0.02 
 
a Adjusted results are presented. 
 
Abbreviations: CI, confidence interval; CV, cardiovascular; DOPPS, Dialysis Outcome Practice Patterns Study; HEMO Study, Hemodialysis Study; HR, hazard 
ratio; MI, myocardial infarction; OR, odds ratio; PAAD, Pharmaceutical Assistance to the Aged and Disabled program in New Jersey; PACE, Pharmaceutical 





CHAPTER 3: AN OVERVIEW OF RESEARCH METHODS 
Overview 
This section provides an overview of the study methods and analytic approaches used in 
this dissertation. Detailed research methods for each respective dissertation aim are presented in 
Chapters 4, 5 and 6.  This project was approved by the University of North Carolina at Chapel Hill 
Institutional Review Board (#15-2651). A waiver of consent was granted due to the study’s large 
size, data anonymity, and retrospective nature. All statistical analyses were preformed using SAS, 
version 9.4 (SAS Institute Inc., Cary, NC). 
 
Data source 
The data source for this dissertation was a linked database containing information on over 
500,000 patients with ESRD that was created by merging data from the clinical research database 
of a large U.S. dialysis provider (DaVita Healthcare Partners, Inc.) with the U.S. Renal Data 
System (USRDS) at the patient level. 
DaVita Clinical Research database 
DaVita HealthCare Partners Inc. is the second largest dialysis provider in the U.S. and 
owns over 1,500 outpatient dialysis clinics located across the country. Their database captures 
detailed clinical, laboratory, and treatment data on patients receiving hemodialysis treatments at 
their facilities. Demographic information is documented at the time of admission to a DaVita 
facility by unit personnel. Comorbid conditions are routinely assessed and updated by attending 




Laboratory data are measured at the time of admission to a DaVita dialysis unit and then biweekly 
or monthly thereafter. Hemodialysis treatment parameters are recorded on a treatment-to-treatment 
basis. 
United States Renal Data System database 
The USRDS is a national data system that collects, analyzes and distributes information 
about the treatment of ESRD in the United States. The USRDS data include: the Medical Evidence 
Report Form (a patient history form completed upon enrollment into the Medicare ESRD 
program), the Medicare Enrollment database (a repository of Medicare beneficiary enrollment and 
entitlement data), the ESRD Death Notification Form (the official form for reporting deaths of 
ESRD patients) and Medicare standard analytic files (final action administrative claims data 
including Medicare Parts A, B and D). 
 
Aim 1 methods (patterns of beta blocker use) 
Understanding the patterns of medication use after therapy initiation is critical in 
comparative effectiveness/safety studies of chronic disease medications. Sustained medication 
efficacy depends on continual drug exposure. The occurrence of clinical outcomes and adverse 
events are often contingent on longitudinal drug exposure (i.e. time on therapy, and current therapy 
utilization). Prior studies evaluating beta blocker prescription patterns assessed medication use at 
a single time-point. Thus, Aim 1 was an investigation of the long-term beta blocker utilization 
patterns in the hemodialysis population to: 1A) determine which beta blocker subtypes (e.g. non-
selective, cardioselective, and alpha beta blockers) and generic products are most commonly 
initiated; 1B) estimate the cumulative incidence of beta blocker discontinuation and switching after 
beta blocker initiation, overall, and among carvedilol and metoprolol initiators (separately); 1C) 




overall, and among carvedilol and metoprolol discontinuers (separately). The findings from Aim 
1 analyses enabled us to gain a thorough understanding of the dynamic nature of beta blocker 
utilization and informed the designs of Aims 2 and 3 of this dissertation. 
Study population and design 
Aim 1A (beta blocker initiation) and Aim 1B (beta blocker discontinuation and switching) 
We conducted a retrospective cohort study using a new-user design.77 We describe the most 
commonly initiated beta blocker sub-classes and generic products in the hemodialysis population. 
We also estimate the 1-year cumulative incidence of beta blocker discontinuation and switching 
among individuals receiving maintenance hemodialysis. First, using Medicare Part D claims, we 
identified dialysis patients treated at the large dialysis organization who initiated oral beta blocker 
therapy (acebutolol, atenolol, betexolol, bisoprolol, carvedilol, labetalol, metoprolol, propranolol, 
pindolol, nadolol, nebivolol, sotalol, timolol) from January 1, 2007 to December 30, 2012 
following a 180-day baseline period free of any documented oral beta blocker use (i.e. a washout 
period). We then applied the following exclusion criteria: 1) age < 18 years old at the start of the 
baseline period, 2) dialysis vintage ≤ 90 days at the start of the baseline period, 3) lack of 
continuous Medicare Part A, B and D coverage during the baseline period, 4) receipt of home 
hemodialysis or peritoneal dialysis during the baseline period, 5) receipt of < 6 center-based 
hemodialysis treatments in the last 30 days of the baseline period, 6) receipt of hospice care during 
the baseline period, and 7) missing demographic or baseline laboratory data. In analyses 
considering carvedilol and metoprolol initiators (termed the sub-cohort), patients who initiated a 
beta blocker other than carvedilol or metoprolol were excluded. Thus, the full study cohort 




in overall beta blocker use assessments), and the sub-cohort was restricted to carvedilol and 
metoprolol new-users (used in assessments of carvedilol and metoprolol use). 
Aim 1C (beta blocker re-initiation) 
In full cohort analyses, the 180-day cumulative incidence of beta blocker re-initiation was 
assessed in patients who discontinued any beta blocker medication. In sub-cohort analyses, the 
180-day cumulative incidence of blocker re-initiation was assessed in patients who discontinued 
carvedilol or metoprolol. 
Exposure 
In Aim 1A we classified beta blocker initiators by subtype, including non-selective beta 
blockers (propranolol, pindolol, nadolol, sotalol, timolol), cardioselective beta blockers 
(acebutolol, atenolol, betexolol, bisoprolol, metoprolol, nebivolol) and alpha-beta blockers 
(carvedilol, labetalol), and also described the proportion beta blocker new-users who initiated each 
respective generic product.  
In Aims 1B (discontinuation and switching) and 1C (re-initiation), the exposure of interest 
was initiation any beta blocker (including all non-selective, cardioselective and alpha-beta 
blockers) in overall analyses, and carvedilol or metoprolol initiation in sub-cohort analyses.  
Outcomes 
Longitudinal beta blocker utilization was assessed by tracking Medicare Part D 
prescription claims post-index date. We only considered the first occurrence of each outcome 
during follow-up. 
Discontinuation 
In the full study cohort, we assessed the 1-year beta blocker discontinuation rate (i.e. a gap 




any beta blocker medication, regardless of switching between individual agents. Discontinuation 
event occurred when the days supply of beta blocker therapy post-index date was exhausted for 
greater than the specified grace period (i.e. 30, 60 or 90 days) without subsequent dispensing of 
any beta blocker. The end of the specified grace period was considered the discontinuation date. 
In the sub-cohort, we assessed 1-year rates of carvedilol and metoprolol discontinuation 
(separately). A patient was classified as a discontinuer when the days supply of their index beta 
blocker was exhausted for greater than the specified grace period (i.e. 30, 60 or 90 days) without 
a subsequent dispensing of the same medication. 
For all discontinuation analyses, we determine discontinuation dates using two different 
analytic approaches: 1) using Medicare Part D prescription claims only (ignoring time periods 
spent in the hospital or skilled nursing facility), and 2) assuming patients remained beta blocker 
therapy during hospital and skilled nursing facility admissions. The latter approach used both 
prescription claims and Medicare Part A/B claims (to identify inpatient hospital and skilled nursing 
facility admissions).  
Switching 
The 1-year rate of beta blocker switching was only considered in the sub-cohort of 
carvedilol or metoprolol initiators. A switching event was defined as changing beta blocker 
medications during follow-up (i.e. the patient fills a prescription for a non-index beta blocker) A 
patient was considered at risk for a switching event during times of continuous medication use, 
including the specified grace periods. A switching event that occurred after a treatment gap was 
not considered. Carvedilol initiators were classified as switchers if they filled a prescription for a 




switchers if they filled a prescription for a beta blocker other than metoprolol during follow-up. 
The date of switching was assigned as the date of the non-index beta blocker fill. 
Re-initiation 
A re-initiation event could only occur in patients who discontinued therapy due to a gap in 
beta blocker treatment (defined above). A patient was at risk to re-initiate once, after the first 
discontinuation event. In overall analyses, re-initiation was defined as the presence of a 
prescription claim for any beta blocker following the first episode of beta blocker of 
discontinuation in the full study cohort. In sub-cohort analyses, re-initiation was defined as the 
presence of a prescription claim for any beta blocker following the first episode of carvedilol or 
metoprolol discontinuation.  
Baseline covariates 
Baseline covariates, including patient demographics, comorbid conditions, laboratory data, 
dialysis treatment parameters, and prescription medication use, were obtained during the 180-day 
baseline period prior to beta blocker initiation using both USRDS and large dialysis organization 
data.  
Censoring events 
Aim 1B (beta blocker discontinuation and switching) and Aim 1C (beta blocker re-initiation) 
Censoring events included: kidney transplantation, dialysis modality change (to peritoneal 
or home hemodialysis); recovery of renal function; loss of Medicare Part A, B or D coverage; 
being lost to follow-up; reaching 1-year of follow-up after the index date for discontinuation and 
switching analyses, and reaching in 180-days of follow-up after the discontinuation date for re-






Aim 1B (beta blocker discontinuation and switching) 
In full cohort of all beta blocker initiators, all-cause death was treated as a competing risk 
in analyses when assessing beta blocker discontinuation. In the sub-cohort of carvedilol and 
metoprolol initiators: 1) all-cause death and index beta blocker switching were considered 
competing events when assessing index carvedilol and metoprolol discontinuation; and 2) all-
cause death and index beta blocker discontinuation were considered competing events when 
assessing beta blocker switching.  
Aim 1C (beta blocker re-initiation) 
In the cohort of patients who discontinued any index beta blocker medication, all-cause 
death was treated as a competing risk. In the sub-cohort of patients who discontinued index 
carvedilol and metoprolol therapy, all-cause death and re-initiation of a non-index beta blocker 
were treated as competing risks. 
Statistical analysis 
Baseline characteristics of the full study cohort and in the sub-cohort of carvedilol and 
metoprolol initiators (separately) were presented to characterize the study populations of interest.  
Categorical variables were presented as count (%) and continuous variables were presented as 
mean ± standard deviation. The crude 1-year cumulative incidence of therapy discontinuation, and 
switching, accounting for applicable competing risks (specified above), was estimated. Individuals 
were followed forward in historical time from the index date to the first occurrence of a study 
outcome, censoring event or competing event (when applicable). The crude 180-day cumulative 




historical time starting on the day immediately following the discontinuation date until the first 
occurrence of beta blocker re-initiation, a censoring event or a competing event (when applicable). 
Aim 2 methods (beta blocker adherence and mortality) 
Non-adherence to prescription medications leads to poor outcomes, including increased 
adverse event rates, suboptimal long-term clinical outcomes, as well as higher healthcare 
utilization and costs.78, 79 Administrative claims data are often used to evaluate and study 
medication adherence across wide range of patient populations.42, 43 One of the most common 
claims-based adherence metrics is the proportion of days covered, or PDC. Typically, PDC is 
calculated using prescription pharmacy claims data by adding the number of days that a patient 
has medication available to them (based on the date a prescription was dispensed and its days 
supply) during a set period of observation, divided by the number of days in the observation period. 
This standard PDC calculation approach ignores time periods spent in hospital or a skilled nursing 
facility. In these settings, chronic disease medications, such as beta blockers, are provided to 
patients by hospital inpatient or skilled nursing facility pharmacies. Prescription insurance-based 
home medication supplies obtained from community pharmacies are not utilized. Thus, in 
populations with high rates of hospital and skilled nursing facility admissions (e.g. hemodialysis 
patients), the standard PDC metric may misestimate the time patients have chronic disease 
medications available to them. In Aim 2 we examined the association between beta blocker 
adherence (PDC ≥ 80%) versus non-adherence (PDC < 80%), and all-cause mortality when the: 
1A) PDC was computed using standard methods (i.e. using administrative pharmacy claims only); 
and 2B) PDC was computed using modified methods (i.e. using administrative pharmacy claims 
and also accounting for time periods when patients were admitted to the hospital or a skilled 




potential importance of computing a modified-version of the PDC (i.e. accounting for time spent 
in the hospital or a skilled in PDC calculations) when evaluating medication adherence—mortality 
associations in populations that experience high rates of hospital and/or skilled nursing facility 
admissions (e.g. hemodialysis patients). 
Study design and population 
We used a retrospective cohort design with a 180-day baseline period, 180-day exposure 
assessment period and 1-year follow-up period to study the association between beta blocker 
adherence versus non-adherence and all-cause mortality among individuals receiving maintenance 
hemodialysis. First, using Medicare Part D claims, we identified dialysis patients treated at the 
large dialysis organization who initiated oral beta blocker therapy (acebutolol, atenolol, betexolol, 
bisoprolol, carvedilol, labetalol, metoprolol, propranolol, pindolol, nadolol, nebivolol, sotalol, 
timolol) from January 1, 2007 to December 30, 2012 following a 180-day baseline period free of 
any documented oral beta blocker use (i.e. a washout period). We then applied the following 
exclusion criteria: 1) age < 18 years old at the start of the baseline period, 2) dialysis vintage ≤ 90 
days at the start of the baseline period, 3) lack of continuous Medicare Part A, B and D coverage 
during the baseline and exposure periods, 4) receipt of home hemodialysis or peritoneal dialysis 
during the baseline or exposure periods, 5) receipt of < 6 center-based hemodialysis treatments in 
the last 30 days of the baseline period, 6) receipt of hospice care during the baseline or exposure 
periods, 7) missing demographic or baseline laboratory data, and 8) experiencing death or a 
censoring event during the exposure period. Thus, the study cohort consisted of prevalent, adult 
hemodialysis patients who did not experience a censoring event and survived the 180-day exposure 





Study exposure, outcome and covariates 
The exposure of interest, beta blocker adherence (PDC ≥ 80%) versus non-adherence (PDC 
<80%) was determined during the 180-day exposure assessment period using two different 
methodologies, a standard approach (using only Medicare Part D prescription claims data) and a 
modified approach (using Medicare Part D prescription claims data and Medicare Part A/B data 
to account for time periods where were admitted to the hospital or a skilled nursing facility). Under 
both paradigms, PDC was computed at the patient level as the: [number of days in the in the 
exposure period where a beta blocker was available / 180 days] x 100%, and was then 
dichotomized at the 80% high adherence threshold.  
The study outcome of interest was 1-year all-cause mortality and was defined as death due 
to any cause. Dates of death were ascertained from the USRDS Patients file. This data file contains 
information derived from ESRD Death Notification Form (Centers for Medicare & Medicaid 
Services (CMS) Form 2746, the official form for reporting ESRD patient deaths to CMS).  
Baseline covariates, including patient demographics, comorbid conditions, laboratory data, 
dialysis treatment parameters, and prescription medication use, were obtained during the 180-day 
baseline period prior to beta blocker initiation using both USRDS and large dialysis organization 
data. 
Censoring events 
Censoring events included: kidney transplantation, dialysis modality change (to peritoneal 
or home hemodialysis), recovery of renal function, loss of Medicare Part A, B or D coverage, 
being lost to follow-up, reaching 1-year of follow-up post-exposure period, or study end 






Baseline characteristics were described by adherence group (for both standard and 
modified PDC) as count (%) for categorical variables and mean ± standard deviation for 
continuous variables. In primary analyses, multivariable Cox proportional hazards regression 
models were used to examine the association between beta blocker adherence (PDC > 80%) versus 
non-adherence (PDC < 80%) and 1-year all-cause mortality when: 1) PDC was computed using 
standard methods, and 2) PDC was computed using modified methods (accounting for inpatient 
hospital and skilled nursing facility admissions). Patients were followed forward in historical time 
starting on the day immediately following the end of the exposure assessment period to the first 
occurrence of a study outcome or censoring event. Several sensitivity analyses were conducted to 
assess the robustness of our primary study findings. 
 
Aim 3 methods (comparative study of carvedilol versus metoprolol initiation and mortality) 
Pharmacologic and pharmacokinetic differences between carvedilol and metoprolol may 
alter their medication safety and efficacy profiles in the setting of ESRD. Pharmacologically, 
carvedilol and metoprolol differ with respect to their beta-adrenergic receptor selectivity and 
vasodilatory capabilities. Kinetically, physiochemical factors, such as molecular size, 
hydrophilicity, plasma protein binding, and volume of distribution influence the extent of 
carvedilol and metoprolol clearance by the hemodialysis procedure. These key factors may 
plausibly alter the hemodynamic and antiarrhythmic risk-benefit profiles of carvedilol and 
metoprolol therapy in the setting of ESRD. In Aim 3 we evaluate the association between 
carvedilol versus metoprolol initiation and 1-year all-cause and cardiovascular mortality, overall 




heart failure, and a recent myocardial infraction). The results from this study will provide much 
needed information to guide carvedilol and metoprolol prescribing in the hemodialysis population.   
Study design and population 
We conducted a retrospective cohort study using a new-user design77 to investigate the 
association between carvedilol versus metoprolol initiation and 1-year all-cause and 
cardiovascular mortality (separately) among individuals receiving maintenance hemodialysis. 
First, using Medicare Part D claims, we identified dialysis patients treated at the large dialysis 
organization who initiated oral beta blocker therapy (acebutolol, atenolol, betexolol, bisoprolol, 
carvedilol, labetalol, metoprolol, propranolol, pindolol, nadolol, nebivolol, sotalol, timolol) from 
January 1, 2007 to December 30, 2012 following a 180-day baseline period free of any documented 
oral beta blocker use (i.e. a washout period). We then applied the following exclusion criteria: 1) 
age < 18 years old at the start of the baseline period, 2) dialysis vintage ≤ 90 days at the start of 
the baseline period, 3) lack of continuous Medicare Part A, B and D coverage during the baseline 
period, 4) receipt of home hemodialysis or peritoneal dialysis during the baseline period, 5) receipt 
of < 6 center-based hemodialysis treatments in the last 30 days of the baseline period, 6) receipt 
of hospice care during the baseline period, 7) missing demographic or laboratory data, and 8) 
initiation of a beta blocker other than carvedilol or metoprolol. Thus, the study cohort consisted of 
prevalent, adult hemodialysis patients who were carvedilol or metoprolol new-users.  
Exposure, outcome and covariates 
The exposures of interest were carvedilol and metoprolol initiation. The index date was 
designated as the date of the first carvedilol or metoprolol prescription after the baseline period.  
Study outcomes of interest were 1-year all-cause and cardiovascular mortality (assessed 




was defined death due to: acute myocardial infarction, pericarditis, atherosclerotic heart disease, 
cardiomyopathy, cardiac arrhythmia, cardiac arrest, valvular heart disease, pulmonary edema due 
to exogenous fluid, congestive heart failure, pulmonary embolus or stroke. Dates of death and 
cause of death information were ascertained from the USRDS Patients file. This data file contains 
information derived from the ESRD Death Notification Form (CMS Form 2746, the official form 
for reporting ESRD patient deaths to CMS). 
Baseline covariates, including patient demographics, comorbid conditions, laboratory data, 
dialysis treatment parameters, and prescription medication use, were obtained during the 180-day 
baseline period prior to beta blocker initiation using both USRDS and large dialysis organization 
data. 
Subgroups 
Subgroups of interest included individuals with the main cardiovascular indications for 
beta blocker therapy: hypertension, atrial fibrillation, heart failure, and a recent myocardial 
infarction. Subgroup classifications were determined based upon patients’ baseline comorbid 
status using International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes 
obtained from USRDS Medicare Part A/B data. 
Censoring events 
Censoring events included: kidney transplantation, dialysis modality change (to peritoneal 
or home hemodialysis), recovery of renal function, loss of Medicare Part A, B or D coverage, 
being lost to follow-up, reaching 1-year of follow-up post-exposure period, or study end 







Baseline characteristics were described across carvedilol and metoprolol initiators as count (%) 
for categorical variables and mean ± standard deviation for continuous variables. Baseline 
covariate distributions were compared using standardized differences. A standardized difference 
>0.1 represents meaningful imbalance between treatment groups.80 
In primary analyses, we used an intent-to-treat approach to evaluate the association 
between carvedilol (versus metoprolol) initiation and 1-year all-cause and cardiovascular 
mortality. Cox proportional hazards models were used to assess the study medication—all-cause 
mortality association.  Fine and Gray proportional subdistribution hazards models81 that treated 
non-cardiovascular death as a competing risk were used to assess the study medication—
cardiovascular mortality association.  Both models estimate HRs and their 95% CIs. Inverse 
probability of treatment (IPT) weighting was used to control for confounding. We used 
multivariable logistic regression to calculate the predicted probability (i.e. propensity score) of 
receiving carvedilol (versus metoprolol) as a function of baseline covariates. Propensity scores 
were used to generate IPT weights.82 We estimated adjusted HRs by applying IPT weights in 
regression models. In addition, several sensitivity analyses were performed to assess the robustness 
of our primary study results. We also conducted a post hoc analysis to evaluate potential 











CHAPTER 4: RESULTS AIM 1 
Introduction 
Understanding the patterns of medication use after therapy initiation is critical in 
comparative effectiveness/safety studies of chronic disease medications. Sustained medication 
efficacy depends on continual drug exposure. The occurrence of clinical outcomes and adverse 
events are often contingent on longitudinal drug exposure (i.e. time on therapy and current therapy 
utilization). The majority of epidemiologic studies evaluating beta blocker utilization in the 
hemodialysis population have been cross-sectional in nature, and evaluated the beta blocker class 
as a whole, and provide little, if any information on the utilization patterns of beta blocker 
subclasses or individual agents.5, 28-41 In a cohort of maintenance hemodialysis patients initiating 
beta blocker therapy we describe: 1) which beta blocker subtypes (e.g. non-selective, 
cardioselective, and alpha beta blockers) and generic products are the most commonly initiated, 





The study data were extracted from the clinical database of a large U. S. dialysis 
organization and the USRDS. Data were linked at the patient level.  The dialysis organization 
operates over 1,500 outpatient dialysis clinics throughout the nation. Its database captures detailed 




biweekly or monthly basis. Hemodialysis treatment parameters are recorded on a treatment-to-
treatment basis. The USRDS is a national ESRD surveillance system that includes: the Medical 
Evidence and ESRD Death Notification forms, the Medicare Enrollment database (a repository of 
Medicare beneficiary enrollment and entitlement data), and Medicare standard analytic files (final 
action administrative claims data including Medicare Parts A, B and D). 
Study population and design 
Beta blocker discontinuation and switching  
We conducted a retrospective cohort study using a new-user design.77 We describe the most 
commonly initiated beta blocker sub-classes and generic products in the hemodialysis population. 
We also estimate the 1-year cumulative incidence of beta blocker discontinuation and switching 
among individuals receiving maintenance hemodialysis (Figure 4.1). First, using Medicare Part D 
claims, we identified dialysis patients treated at the large dialysis organization who initiated oral 
beta blocker therapy (acebutolol, atenolol, betexolol, bisoprolol, carvedilol, labetalol, metoprolol, 
propranolol, pindolol, nadolol, nebivolol, sotalol, timolol) from January 1, 2007 to December 30, 
2012 following a 180-day washout period free of any documented oral beta blocker use. We then 
applied the following exclusion criteria: 1) age < 18 years old at the start of the baseline period, 2) 
dialysis vintage ≤ 90 days at the start of the baseline period, 3) lack of continuous Medicare Part 
A, B and D coverage during the baseline period, 4) receipt of home hemodialysis or peritoneal 
dialysis during the baseline period, 5) receipt of < 6 center-based hemodialysis treatments in the 
last 30 days of the baseline period, 6) receipt of hospice care during the baseline period, and 7) 
missing demographic or baseline laboratory data. In analyses considering carvedilol and 
metoprolol initiators (termed the sub-cohort), patients who initiated a beta blocker other than 




hemodialysis patients who were new-users of any beta blocker (used in overall beta blocker use 
assessments), and the sub-cohort was restricted to carvedilol and metoprolol new-users (used in 
assessments of carvedilol and metoprolol use). 
Beta blocker re-initiation 
In full cohort analyses, the 180-day cumulative incidence of beta blocker re-initiation was 
assessed in patients who discontinued any beta blocker medication. In sub-cohort analyses, the 
180-day cumulative incidence of blocker re-initiation was assessed in patients who discontinued 
carvedilol or metoprolol. Study designs for re-initiation analyses are depicted in Figure 4.2. 
Exposure 
In analyses characterizing beta blocker initiation, beta blocker initiators were classified by:  
1) subtype, including non-selective beta blockers (propranolol, pindolol, nadolol, sotalol, timolol), 
cardioselective beta blockers (acebutolol, atenolol, betexolol, bisoprolol, metoprolol, nebivolol) 
and alpha-beta blockers (carvedilol, labetalol), and 2) and individual generic products.  
When assessing beta blocker discontinuation, switching and re-initiation, the exposure of 
interest was initiation any beta blocker in overall analyses (including all non-selective, 
cardioselective and alpha-beta blockers), and carvedilol or metoprolol initiation in sub-cohort 
analyses.  
Outcomes 
Longitudinal beta blocker utilization was assessed by tracking Medicare Part D 








In the full study cohort (all beta blocker initiators), we assessed the 1-year rate of beta 
blocker discontinuation (i.e. a gap in beta blocker therapy). In these analyses, we were interested 
in assessing continuous use of any beta blocker medication. In these analyses switching between 
individual agents within the beta blocker class was allowed. A discontinuation event occurred 
when the days supply of beta blocker therapy post-index date was exhausted for greater than the 
specified grace period (i.e. 30, 60 or 90 days) without subsequent dispensing of any beta blocker. 
The end of the specified grace period was considered the discontinuation date. An example of beta 
blocker discontinuation is illustrated in Panel A of Figure 4.3. 
In the sub-cohort (carvedilol and metoprolol initiators only), we assessed 1-year carvedilol 
and metoprolol discontinuation (separately). A patient was classified as a discontinuer when the 
days supply of the index beta blocker was exhausted for greater than the specified grace period 
(i.e. 30, 60 or 90 days) without a subsequent dispensing of the same medication. 
For all discontinuation analyses, we determined discontinuation dates using two different 
analytic approaches: 1) using Medicare part D prescription claims only, and 2) using Medicare D 
claims and Medicare Part A/B claims to account for time periods that patients spent in the hospital 
or a skilled nursing facility. The latter expanded claims-based approach facilitated the 
identification of inpatient hospital and skilled nursing facility admissions. In these analyses, we 
assumed that patients remained on beta blocker therapy during hospital and skilled nursing facility 
admissions. Figure 4.4 depicts how the beta blocker days supply values were adjusted for hospital 







The 1-year cumulative incidence of beta blocker switching was only considered in the sub-
cohort of carvedilol or metoprolol initiators. A switching event was defined as changing beta 
blocker medications during follow-up (i.e. the patient fills a prescription for a non-index beta 
blocker). A patient was considered at risk for a switching event during times of continuous 
medication use, including the specified grace periods. A switching event that occurred after a 
treatment gap was not considered. Carvedilol initiators were classified as switchers if they filled a 
prescription for a beta blocker other than carvedilol during follow-up. Metoprolol initiators were 
classified as switchers if they filled a prescription for a beta blocker other than metoprolol during 
follow-up. The date of switching was assigned as the date of the non-index beta blocker fill. An 
example of beta blocker switching is illustrated in Panel B of Figure 4.3. 
Re-initiation 
A re-initiation event could only occur in patients who discontinued therapy due to a gap in 
beta blocker treatment (defined above). A patient was at risk to re-initiate once, after the first 
discontinuation event. In overall analyses, re-initiation was defined as the presence of a 
prescription claim for any beta blocker following the first episode of beta blocker of 
discontinuation in the full study cohort. In sub-cohort analyses, re-initiation was defined as the 
presence of a prescription claim for any beta blocker following the first episode of carvedilol or 
metoprolol discontinuation. An depiction of beta blocker re-initiation is illustrated in Panel C of 
Figure 4.3. 
Baseline covariates 
Baseline covariates, including patient demographics, comorbid conditions, laboratory data, 




baseline period prior to beta blocker initiation using both USRDS and large dialysis organization 
data (Appendix: Supplemental Table 1).  
Censoring events 
In all analyses, censoring events included: 1) kidney transplantation, 2) dialysis modality 
change (to peritoneal or home hemodialysis), 3) recovery of renal function, 4) loss of Medicare 
Part A, B or D coverage, 5) being lost to follow-up, 6) reaching 1-year of follow-up after the index 
date for discontinuation and switching analyses and reaching in 180-days of follow-up after the 
discontinuation date for re-initiation analyses, or 7) study end (December 31, 2012).  
Competing risks 
 A competing risk is an event that either hinders the observation of the event of interest or 
modifies the chance that this event occurs.  
Beta blocker discontinuation and switching 
In the full cohort (all beta blocker initiators) all-cause death was treated as a competing 
risk in analyses when assessing beta blocker discontinuation. In the sub-cohort of carvedilol and 
metoprolol initiators: 1) all-cause death and index beta blocker switching were considered 
competing events when assessing index carvedilol and metoprolol discontinuation; and 2) all-
cause death and index beta blocker discontinuation were considered competing events when 
assessing beta blocker switching.  
Beta blocker re-initiation 
In the cohort of patients who discontinued any index beta blocker medication, all-cause 
death was treated as a competing risk. In the sub-cohort of patients who discontinued index 
carvedilol or metoprolol therapy, all-cause death and re-initiation of a non-index beta blocker were 





Baseline characteristics of the full study cohort and the sub-cohort were presented to 
characterize the main study populations. Categorical variables are presented as count (%) and 
continuous variables are presented as mean ± standard deviation. The crude 1-year cumulative 
incidence of therapy discontinuation, and switching, accounting for applicable competing risks 
(specified above) was estimated. Individuals were followed forward in historical time from the 
index date to the first occurrence of a study outcome, censoring event or competing event (when 
applicable). The crude 180-day cumulative incidence of beta blocker re-initiation was estimated. 
Study patients were followed forward in historical time starting on the day immediately following 
the discontinuation date until the first occurrence of beta blocker re-initiation, a censoring event 
or a competing event (when applicable). 
 
Results 
Assessment of beta blocker initiation 
Figure 4.5 displays a flow diagram of the study cohort selection. A total of 33,888 
hemodialysis patients initiated beta blocker therapy between 2007 and 2012, including 477 (1.4%) 
non-selective beta blocker, 20,764 (61.3%) cardioselective and 12,643 (37.3%) beta blocker 
initiators (Table 4.1). Overall, metoprolol (51.6%) and carvedilol (28.2%) were the most 
commonly initiated agents. Baseline characteristics for the full study cohort (all beta blocker 
initiators) and the sub-cohort (carvedilol and metoprolol initiators) are presented in Table 4.2. 
Both cohorts are similar to the broader U.S. hemodialysis population with respect to age, sex and 





Overall assessment of beta blocker discontinuation and re-initiation 
When assessing the beta blocker class as a whole, the 1-year cumulative incidence of 
therapy cessation post-index date was common, ranging from 40.1% to 68.5% depending on the 
discontinuation definition employed (Table 4.3). In particular, rates of beta blocker 
discontinuation were the highest when a 30-day grace period was used to define therapy cessation, 
and were the lowest when a 90-day grace period was used. Regardless of the grace period used to 
define discontinuation, making the assumption that patients continued beta blocker therapy during 
hospital and skilled nursing facility admissions resulted in slightly lower estimates 1-year beta 
blocker discontinuation as compared to discontinuation estimates based upon prescription fill data 
alone (Table 4.3, Figure 4.6). Furthermore, re-initiation of beta blocker therapy, after a treatment 
gap, also occurred frequently (Table 4.4, Figure 4.7). The 180-day cumulative incidence of 
restarting any blocker beta medication ranged from 45.7% to 63.4%.   
Assessment of carvedilol and metoprolol discontinuation, switching and re-initiation 
Similar to overall analyses, carvedilol and metoprolol discontinuation were common 
(Table 4.5, Figure 4.8). Depending on definition, discontinuation ranged from 35.0% to 64.7% 
among carvedilol initiators, and ranged from 39.2% to 66.3% among metoprolol initiators. 
Switching to a non-index beta blocker was uncommon, and occurred at similar rates among 
carvedilol and metoprolol initiators (Table 4.6, Figure 4.9). Index beta blocker re-initiation was 
slightly higher among carvedilol discontinuers as compared to metoprolol discontinuers after their 








Implications for subsequent dissertation aims 
Dissertation aim 2 
We found that 1-year beta blocker therapy cessation post-index date (i.e. discontinuation 
from the beta blocker class as a whole) was common. Rates of 180-day beta blocker re-initiation 
after an initial treatment gap we high. Based on these findings beta blocker utilization post-index 
date in this cohort of maintenance hemodialysis patients was dynamic. Thus, a study assessing 
beta blocker adherence and mortality (i.e. Aim 2 of this dissertation) will be feasible. Notably, 
regardless of the grace period used to define discontinuation, making the assumption that patients 
continued beta blocker therapy during hospital and skilled nursing facility admissions resulted in 
slightly lower estimates of 1-year beta blocker discontinuation as compared to discontinuation 
estimates based upon prescription fill data alone. These findings suggest that administrative 
claims-based studies assessing beta blocker (or any chronic medication) adherence in the 
hemodialysis population should consider accounting for hospital and skilled nursing facility 
admissions when longitudinally tracking beta blocker (or any chronic medication) utilization as a 
means to estimate medication adherence.  
Dissertation Aim 3 
Carvedilol and metoprolol were the most commonly initiated beta blockers (79.7% of all 
beta blocker new-users). Since, these beta blockers have similar indication profiles in the setting 
of ESRD a comparative study evaluating the association between carvedilol and metoprolol 
initiation and mortality among individuals receiving maintenance hemodialysis (i.e. Aim 3 of this 
dissertation) will likely be feasible and of high clinical interest. Even though carvedilol and 
metoprolol therapy cessation was common, we found that a high proportion of carvedilol and 
metoprolol discontinuers re-initiated on their index beta blocker medication. Furthermore, among 




uncommon. These findings suggest that after the initial carvedilol or metoprolol prescription, 
patients tend to remain on their index beta blocker even after gaps in therapy. Thus, when assessing 
the association between carvedilol and metoprolol initiation and mortality, an appropriate primary 


























Table 4.1 Frequency of beta blocker initiation by subclass and generic product  
Beta blocker subclass and generic product n (%) 
 
Non-selective 
   Propranolol 
   Nadolol 





   309 (0.9%) 
   84 (0.3%) 
   84 (0.3%) 
Cardioselective 
   Metoprolol 
      Metoprolol tartrate 
      Metoprolol succinate 
   Atenolol 
   Nebivolol 
   Otherb 
 
20,764 (61.3%) 
   17,506 (51.6%) 
      11,736 (34.6%) 
      5,770 (17.0%) 
   2,805 (8.3%) 
   352 (1.0%) 
   105 (0.3%) 
Alpha-beta 
   Carvedilol 
   Labetalol 
 
12,643 (37.3%) 
   9,558 (28.2%) 
   3,085 (9.1%) 
There were a total of 33,888 beta blocker initiators identified. 
a Other non-selective beta blockers include: sotalol, pindolol, timolol 


















Table 4.2 Characteristics of the Aim 1 full study cohort and sub-cohort 
Characteristic 
Full study cohort 
n = 33,888 
Sub-cohort 
n = 27,064 
Age (years) 58.7 ± 15.0 59.6 ± 14.7 
Female 15,835 (46.7%) 12,630 (46.7%) 
Race   
   White 16,961 (50.1%) 13,902 (51.4%) 
   Black 15,015 (44.3%) 11,605 (42.9%) 
   Other 1,912 (5.6%) 1,557 (5.8%) 
Hispanic ethnicity 6,580 (19.4%) 5,276 (19.5%) 
Low-income subsidy 26,238 (77.4%) 20,783 (76.8%) 
Year index beta blocker was 
prescribed 
  
   2007 6,109 (18.0%) 4,703 (17.4%) 
   2008 5,631 (16.6%) 4,396 (16.2%) 
   2009 5,085 (15.0%) 4,001 (14.8%) 
   2010 5,291 (15.6%) 4,220 (15.6%) 
   2011 5,658 (16.7%) 4,656 (17.2%) 
   2012 6,114 (18.0%) 5,088 (18.8%) 
Cause of ESRD   
   Diabetes 15,846 (46.8%) 13,254 (49.0%) 
   Hypertension 9,893 (29.2%) 7,614 (28.1%) 
   Glomerular disease 3,818 (11.3%) 2,845 (10.5%) 
   Other 4,331 (12.8%) 3,351 (12.4%) 
Body mass index     
   < 18.5 kg/m2 1,643 (4.8%) 1,318 (4.9%) 
   18.5 – 24.9 kg/m2 12,485 (36.8%) 9,840 (36.4%) 
   25.0 – 29.9 kg/m2 9,709 (28.7%) 7,739 (28.6%) 
   ≥ 30.0 kg/m2 10,051 (29.7%) 8,167 (30.2%) 
History of prior renal 
transplant 
2,366 (7.0%) 1,706 (6.3%) 
Dialysis vintage   
   < 1.0 year 1,849 (5.5%) 1,530 (5.7%) 
   1.0 – 1.9 years 7,110 (21.0%) 5,823 (21.5%) 
   2.0 – 2.9 years 5,528 (16.3%) 4,446 (16.4%) 
   ≥ 3.0 years 19,401 (57.3%) 15,265 (56.4%) 
Atrial fibrillation 4,188 (12.4%) 3,761 (13.9%) 
Other arrhythmia 2,909 (8.6%) 2,560 (9.5%) 
Angina 595 (1.8%) 512 (1.9%) 
Cancer    1,183 (3.5%) 973 (3.6%) 
Conduction disorder 965 (2.8%) 863 (3.2%) 
COPD/asthma 5,299 (15.6%) 4,499 (16.6%) 
Coronary atherosclerosis 9,132 (26.9%) 8,086 (29.9%) 
Diabetes 17,601 (51.9%) 14,759 (54.5%) 




Heart failure    10,745 (31.7%) 9,358 (34.6%) 
Hypertension 23,994 (70.8%) 19,673 (72.7%) 
Liver disease 1,593 (4.7%) 1,204 (4.4%) 
Myocardial infarction 1,921 (5.7%) 1,793 (6.6%) 
Peripheral artery disease 6,891 (20.3%) 5,878 (21.7%) 
Stroke 3,397 (10.0%) 2,851 (10.5%) 
Valvular disease 2,555 (7.5%) 2,241 (8.3%) 
History of non-compliancea 2,002 (5.9%) 1,615 (6.0%) 
Vascular access   
   Fistula 19,786 (58.4%) 15,699 (58.0%) 
   Graft 8,616 (25.4%) 6,879 (25.4%) 
   Catheter 5,486 (16.2%) 4,486 (16.6%) 
Interdialytic weight gain  
≥ 3 kg   
8,379 (24.7%) 6,573 (24.3%) 
Delivered dialysis treatment 
time < 240 min 
27,074 (79.9%) 21,597 (79.8%) 
Pre-dialysis systolic BP   
   < 130 mmHg  4,090 (12.1%) 3,543 (13.1%) 
   130 – 149 mmHg 9,076 (26.8%) 7,440 (27.5%) 
   150 – 169 mmHg 11,815 (34.9%) 9,259 (34.2%) 
   ≥170 mmHg 8,907 (26.3%) 6,822 (25.2%) 
Recent history of 
intradialytic hypotensionb 
4,317 (12.7%) 3,712 (13.7%) 
Albumin      
   ≤ 3.0 g/dL 1,617 (4.8%) 1,351 (5.0%) 
   3.1 – 4.0 g/dL   21,115 (62.3%) 17,278 (63.8%) 
   > 4.0 g/dL 11,156 (32.9%) 8,435 (31.2%) 
Calcium       
   < 8.5 mg/dL 4,866 (14.4%) 3,835 (14.2%) 
   8.5 – 10.2 mg/dL 4,866 (14.4%) 21,915 (81.0%) 
   > 10.2 mg/dL 1,633 (4.8%) 1,314 (4.9%) 
Phosphorus   
   < 3.5 mg/dL 3,628 (10.7%) 2,995 (11.1%) 
   3.5 – 5.5 mg/dL 18,169 (53.6%) 14,655 (54.1%) 
   > 5.5 mg/dL 12,091 (35.7%) 9,414 (34.8%) 
Potassium   
   < 4.0 mEq/L 3,698 (10.9%) 2,982 (11.0%) 
   4.0 – 6.0 mEq/L 28,896 (85.3%) 23,067 (85.2%) 
   > 6.0 mEq/L 1,294 (3.8%) 1,015 (3.8%) 
Hemoglobin      
   < 9.5 g/dL 2,229 (6.6%) 1,829 (6.8%) 
   9.5 – 12.0 mg/dL 20,963 (61.9%) 16,873 (62.3%) 
   > 12.0 mg/dL 10,696 (31.6%) 8,362 (30.9%) 




Number of medications in 
last 30 days of baseline 
5.4 ± 3.9 5.5 ± 3.9 
Alpha blocker 302 (0.9%) 231 (0.9%) 
ACE inhibitor 7,865 (23.2%) 6,272 (23.2%) 
Angiotensin receptor blocker 3,911 (11.5%) 3,060 (11.3%) 
Calcium channel blocker 11,638 (34.3%) 9,019 (33.3%) 
Central alpha agonist 5,149 (15.2%) 3,758 (13.9%) 
Diuretic 3,720 (11.0%) 3,084 (11.4%) 
Vasodilator 3,833 (11.3%) 2,913 (10.8%) 
Statin 8,451 (24.9%) 7,087 (26.2%) 
Other cholesterol medicationc 1,355 (4.0%) 1,111 (4.1%) 
Digoxin 673 (2.0%) 590 (2.2%) 
Long-acting nitrate 2,389 (7.0%) 2,061 (7.6%) 
Antiplatelet medication 3,907 (11.5%) 3,345 (12.4%) 
Anticoagulant medication 2,535 (7.5%) 2,169 (8.0%) 
Midodrine 605 (1.8%) 542 (2.0%) 
All-covariates were measured during the baseline period prior to beta blocker initiation. Values for categorical 
variables are given as number (%) and as mean ± standard deviation for continuous variables.  
 
a Claims-based definition of non-compliance included ICD-9 discharge diagnosis codes V15.81 (personal history of 
noncompliance with medical treatment, presenting hazards to health) and V45.12 (noncompliance with renal dialysis). 
 
b Patients were considered as having a recent history of intradialytic hypotension if they had an intradialytic nadir 
systolic blood pressure < 90 mmHg in at least 30% of outpatient hemodialysis treatments in the last 30 days of the 
baseline period.57 
 
c Other cholesterol medications included the following non-statin cholesterol medications: bile acid sequestrants, 
cholesterol absorption inhibitors, fibrates and niacin.  
 
Abbreviations: ACE, angiotensin converting enzyme; BP, blood pressure; COPD, chronic obstructive pulmonary 















Table 4.3 1-year cumulative incidence of beta blocker discontinuation 
Grace period use to determine discontinuation 1-year cumulative incidence 
30 days 
   Rx claims only 





   Rx claims only 





   Rx claims only 




This table presents the 1-year cumulative incidence of beta blocker discontinuation in the full study cohort (n = 33,888) 
when a discontinuation event was defined using a 30, 60 and 90-day grace periods. Within each of these grace periods, 
we describe the 1-year cumulative incidence of discontinuation: 1) using prescription claims only (Rx claims only); 
and 2) using prescription claims + Medicare Part A/B claims (to identify inpatient hospital and skilled nursing facility 
admissions), making the assumption that patients remained beta blocker therapy during hospital and skilled nursing 
facility admissions (Rx claims adjusted for admissions). All-cause death was treated as a competing risk. 



















Table 4.4 180-day cumulative incidence of beta blocker re-initiation among beta blocker 
discontinuers 
Grace period used to determine beta blocker 
discontinuationa 
Cohort sizea 180-day cumulative incidence 
30 days 
   Rx claims only 








   Rx claims only 








   Rx claims only 







This table presents the 180-day cumulative incidence of beta blocker re-initiation in the among 6 different cohorts of 
beta blocker discontinuers. All-cause death was treated as a competing risk. 
a The size of each of these cohorts was contingent on the definition that was used to define beta blocker discontinuation 
post-index date. Discontinuation was defined using 30, 60 and 90-day grace periods. Within each of these grace 
periods, 1-year cumulative incidence of discontinuation was determined: 1) using prescription claims only (Rx claims 
only); and 2) using prescription claims + Medicare Part A/B claims (to identify inpatient hospital and skilled nursing 
facility admissions), making the assumption that patients remained beta blocker therapy during hospital and skilled 
nursing facility admissions (Rx claims adjusted for admissions).  




























Table 4.5 1-year cumulative incidence of carvedilol and metoprolol discontinuation  
 1-year cumulative incidence 
Grace period used to determine discontinuation 
Carvedilol 
n = 9,558 
Metoprolol 
n = 17,506 
30 days 
   Rx claims only 








   Rx claims only 








   Rx claims only 







This table presents the 1-year cumulative incidence of beta blocker discontinuation in the sub-cohort of carvedilol and 
metoprolol initiators (n=27,064). Carvedilol and metoprolol discontinuation were considered separately. A 
Discontinuation was defined using 30, 60 and 90-day grace periods. Within each of these grace periods, we describe 
the 1-year cumulative incidence of discontinuation: 1) using prescription claims only (Rx claims only); and 2) using 
prescription claims + Medicare Part A/B claims (to identify inpatient hospital and skilled nursing facility admissions), 
making the assumption that patients remained beta blocker therapy during hospital and skilled nursing facility 
admissions (Rx claims adjusted for admissions). All-cause death and switching to an non-index beta blocker were 
treated as competing risks. 



























Table 4.6 1-year cumulative incidence of switching to a non-index beta blocker among 
carvedilol and metoprolol initiators 
 1-year cumulative incidence 
Grace period used to determine discontinuationa 
Carvedilol 
n = 9,558 
Metoprolol 
n = 17,506 
30 days 
   Rx claims only 








   Rx claims only 








   Rx claims only 







This table presents the 1-year cumulative incidence of switching to a non-index beta blocker discontinuation in the 
sub-cohort of carvedilol and metoprolol initiators (n=27,064). Carvedilol and metoprolol switching were considered 
separately. All-cause death and index beta blocker discontinuation were treated as a competing risk. 
 
a Index beta blocker discontinuation (a competing risk in these analyses) was defined using a 30, 60 and 90-day grace 
periods. Within each of these grace periods, 1-year cumulative incidence of discontinuation was determined: 1) using 
prescription claims only (Rx claims only); and 2) using prescription claims + Medicare Part A/B claims (to identify 
inpatient hospital and skilled nursing facility admissions), making the assumption that patients remained beta blocker 
therapy during hospital and skilled nursing facility admissions (Rx claims adjusted for admissions).  



























Table 4.7 180-day cumulative incidence of index beta blocker re-initiation among 
individuals who were index carvedilol and metoprolol discontinuers 
  180-day cumulative incidence 
Grace period used to determine index 
beta blocker discontinuationa 
Cohort sizea Carvedilol Metoprolol 
30 days 
   Rx claims only 











   Rx claims only 











   Rx claims only 










This table presents the 180-day cumulative incidence of beta blocker re-initiation among 6 different sub-cohorts of 
carvedilol and metoprolol discontinuers. All-cause death was treated as a competing risk. 
a The size of each of these cohorts was contingent on the definition that was used to define beta blocker discontinuation 
post-index date. Discontinuation was defined using a 30, 60 and 90-day grace periods. Within each of these grace 
periods, 1-year cumulative incidence od discontinuation was determined: 1) using prescription claims only (Rx claims 
only); and 2) using prescription claims + Medicare Part A/B claims (to identify inpatient hospital and skilled nursing 
facility admissions), making the assumption that patients remained beta blocker therapy during hospital and skilled 
nursing facility admissions (Rx claims adjusted for admissions).  


















Figure 4.1 Aim 1 study designs for discontinuation and switching analyses 
 
Panel A. Full cohort (includes all beta blocker initiators) 
 
 
Beta blocker initiators were defined as hemodialysis patients who had no record of a beta blocker prescription in the 
previous 180 days (beta blocker washout period). Among these patients, the index date was defined as the date of beta 
blocker initiation. Baseline covariates were identified in the 180-day period prior to the index date. Study follow-up 
began immediately after the index date. 
 




Carvedilol and metoprolol initiators were defined as hemodialysis patients who had no record of a beta blocker 
prescription in the previous 180 days (beta blocker washout period). Among these patients, the index date was defined 
as the date of carvedilol or metoprolol initiation. Baseline covariates were identified in the 180-day period prior to the 
index date. Study follow-up began immediately after the index date. 
 






Figure 4.2 Aim 1 study designs for re-initiation analyses 
 




Beta blocker discontinuation occurred when the days supply of beta blocker therapy post-index date was exhausted 
for greater than a specified grace period (i.e. 30, 60 or 90 days) without subsequent dispensing of any beta blocker. 
The end of the specified grace period was considered the discontinuation date. Study follow-up began immediately 
after the discontinuation date. 
 
 




Carvedilol and metoprolol discontinuation was assessed separately. A patient was classified as a discontinuer when 
the days supply of the index beta blocker was exhausted for greater than the specified grace period (i.e. 30, 60 or 90 
days) without a subsequent dispensing of the same medication. The end of the specified grace period was considered 










Figure 4.3 Illustrative examples of beta blocker discontinuation, switching and re-initiation  
 
Panel A. Discontinuation 
 
Panel B. Switching 
 
Panel C. Re-initiation 
 









Figure 4.4 Illustration of beta blocker days supply adjustment made when patients were 
admitted to the hospital or skilled nursing facility in Aim 1 analyses 
 
 



























Figure 4.6 A representative plot of the 1-year cumulative incidence of beta blocker therapy 
discontinuation 
 
This plot illustrates the 1-year cumulative incidence of beta blocker discontinuation in the full study cohort (n = 
33,888) when a discontinuation event was defined using a 60-day grace period. The black dashed line represents the 
1-year cumulative incidence of discontinuation when therapy cessation was determined using prescription claims only; 
the gray solid line represents the 1-year cumulative incidence of discontinuation when therapy cessation was 
determined using prescription claims + Medicare Part A/B claims (to identify inpatient hospital and skilled nursing 
facility admissions), making the assumption that patients remained beta blocker therapy during hospital and skilled 














Figure 4.7 A representative plot of the 180-day cumulative incidence of beta blocker re-
initiation 
 
This plot illustrates the 1-year cumulative incidence of beta blocker re-initiation among beta blocker discontinuers (n 
= 14,742) when: 1) a discontinuation event was defined using a 60-day grace period; and 2) assuming patients 
continued index beta blocker therapy during applicable hospital and skilled nursing facility admissions. All-cause 
















Figure 4.8 A representative plot of the 1-year cumulative incidence of carvedilol and 
metoprolol discontinuation 
 
This plot illustrates the 1-year cumulative incidence of beta blocker discontinuation in the sub-cohort of carvedilol 
and metoprolol initiators (n = 27,064) when 1) a discontinuation event was defined using a 60-day grace period and 
2) assuming patients continued index beta blocker therapy during applicable hospital and skilled nursing facility 
admissions. The red dashed lines represent the 1-year cumulative incidence of carvedilol discontinuation and the blue 
solid lines represent the 1-year cumulative incidence of metoprolol discontinuation. All-cause death and switching to 















Figure 4.9 A representative plot of the 1-year cumulative incidence of carvedilol and 
metoprolol switching 
 
This plot illustrates the 1-year cumulative incidence of carvedilol and metoprolol switching (assessed separately) in 
the sub-cohort of carvedilol and metoprolol initiators (n = 27,064) when: 1) a discontinuation event was defined using 
a 60-day grace period; and 2) assuming patients continued index beta blocker therapy during applicable hospital and 
skilled nursing facility admissions. The red dashed lines represent the 1-year cumulative incidence of switching to a 
non-carvedilol beta blocker during follow-up among carvedilol initiators. The blue solid line represents the 1-year 
cumulative incidence of switching to a non-metoprolol beta blocker during follow-up among metoprolol initiators. 














Figure 4.10 A representative plot the 1-year cumulative incidence of carvedilol and 
metoprolol re-initiation 
 
In this plot, the hemodialysis patient cohort eligible for re-initiation analyses included 11,110 individuals who 
discontinued index carvedilol or metoprolol therapy due to a gap in treatment of at least 60 days as determined using 
both Medicare Part D prescription and Medicare Part A/B hospital and skilled nursing facility claims (i.e. we assumed 
that patients remained beta blocker therapy during hospital and skilled nursing facility admissions). The red dashed 
lines represent the 180-day cumulative incidence of carvedilol re-initiation among carvedilol discontinuers. The blue 
solid line represents the 180-day cumulative incidence of metoprolol re-initiation metoprolol discontinuers. All-cause 





CHAPTER 5: RESULTS AIM 2 
Introduction 
Non-adherence to prescription medications leads to poor outcomes, including increased 
adverse event rates, suboptimal long-term clinical outcomes, as well as higher healthcare 
utilization and costs.78, 79 Administrative claims data are often used to evaluate and study 
medication adherence across wide range of patient populations, including individuals with kidney 
disease.42, 43 One of the most common claims-based adherence metrics is the proportion of days 
covered, or PDC. Typically, the PDC is calculated using pharmacy claims data by adding the 
number of days that a patient has prescription medication available to them (based on the date a 
prescription was dispensed and its days supply) during a set period of observation, and dividing 
this sum by the number of total days in the observation period. This standard approach for the 
calculation of PDC ignores time periods spent in hospital or a skilled nursing facility. In these 
settings, chronic disease medications, such as beta blockers, are provided to patients by hospital 
inpatient or skilled nursing facility pharmacies. Typically, patients do not use prescription 
insurance-based home medication supplies obtained from community pharmacies during hospital 
or skilled nursing facility. Thus, in populations with high rates of hospital and skilled nursing 
facility admissions (e.g. hemodialysis patients), the standard PDC metric may misestimate the time 
patients have chronic disease medications available to them. In a cohort of hemodialysis patients 
newly initiating beta blocker therapy,  we examine the association between beta blocker adherence 
(PDC ≥ 80%) versus non-adherence (PDC < 80%)  and all-cause mortality when the: 1) PDC is 




is computed using modified methods (i.e. using administrative pharmacy claims and also 
accounting for time periods patients spent the hospital or a skilled nursing facility using Medicare 




The study data were extracted from the clinical database of a large U. S. dialysis 
organization and the USRDS. Data were linked at the patient level. The dialysis organization 
operates over 1,500 outpatient dialysis clinics throughout the nation. Its database captures detailed 
demographic, clinical, laboratory, and dialysis treatment data. Laboratory data are measured on a 
biweekly or monthly basis. Hemodialysis treatment parameters are recorded on a treatment-to-
treatment basis. The USRDS is a national ESRD surveillance system that includes: the Medical 
Evidence and ESRD Death Notification forms, the Medicare Enrollment database (a repository of 
Medicare beneficiary enrollment and entitlement data), and Medicare standard analytic files (final 
action administrative claims data including Medicare Parts A, B and D). 
Study design and population 
We used a retrospective cohort design with a 180-day baseline period, 180-day exposure 
assessment period and 1-year follow-up period to study the association between beta blocker 
adherence and all-cause mortality among individuals receiving maintenance hemodialysis (Figure 
5.1). First, using Medicare Part D claims, we identified dialysis patients treated at the large dialysis 
organization who initiated oral beta blocker therapy (acebutolol, atenolol, betexolol, bisoprolol, 
carvedilol, labetalol, metoprolol, propranolol, pindolol, nadolol, nebivolol, sotalol, timolol) from 
January 1, 2007 to December 30, 2012 following a 180-day washout period free of any 




years old at the start of the baseline period, 2) dialysis vintage ≤ 90 days at the start of the baseline 
period, 3) lack of continuous Medicare Part A, B and D coverage during the baseline and exposure 
periods, 4) receipt of home hemodialysis or peritoneal dialysis during the baseline or exposure 
periods, 5) receipt of < 6 center-based hemodialysis treatments in the last 30 days of the baseline 
period, 6) receipt of hospice care during the baseline or exposure periods, 7) missing demographic 
or baseline laboratory data, and 8) experiencing death or a censoring event during the exposure 
period. Thus, the study cohort consisted of prevalent, adult hemodialysis patients who did not 
experience a censoring event and survived the 180-day exposure assessment period.  
Study exposure, outcome and covariates 
The exposure of interest, beta blocker adherence (PDC ≥ 80%) versus non-adherence (PDC 
< 80%) was determined during the 180-day exposure assessment period using two different 
methodologies, a standard approach (using only Medicare Part D prescription claims data) and a 
modified approach (using Medicare Part D prescription claims data and also Medicare Part A/B 
data to account for time periods when patients were admitted to the hospital or a skilled nursing 
facility). Under both paradigms, PDC was computed at the patient level as the: [number of days in 
the in the exposure period where a beta blocker was available / 180 days] x 100%, and was then 
dichotomized at the 80% high adherence threshold. Individuals’ with a PDC ≥ 80% were 
considered adherent, whereas individuals with a PDC < 80% were considered non-adherent.  
The study outcome of interest was 1-year all-cause mortality. All-cause mortality was 
defined as death due to any cause. Dates of death were ascertained from the USRDS Patients file. 
This data file contains information derived from ESRD Death Notification Form (CMS Form 




Baseline covariates, including patient demographics, comorbid conditions, laboratory data, 
dialysis treatment parameters, and prescription medication use, were obtained during the 180-day 
baseline period prior to beta blocker initiation using both USRDS and large dialysis organization 
data (Appendix: Supplemental Table 1). 
Censoring events 
Censoring events included: kidney transplantation, dialysis modality change (to peritoneal 
or home hemodialysis), recovery of renal function, loss of Medicare Part A, B or D coverage, 
being lost to follow-up, reaching 1-year of follow-up post-exposure period, or study end 
(December 31, 2012).  
Statistical analysis 
Baseline characteristics were described by adherence group (for both standard and 
modified PDC) as count (%) for categorical variables and mean ± standard deviation for 
continuous variables. In primary analyses, multivariable Cox proportional hazards regression 
models were used to examine the association between beta blocker adherence (PDC ≥ 80%) versus 
non-adherence (PDC < 80%) and 1-year all-cause mortality when: 1) PDC was computed using 
standard methods, and 2) PDC was computed using modified methods (accounting for inpatient 
hospital and skilled nursing facility admissions). Patients were followed forward in historical time 
starting on the day immediately following the end of the exposure assessment period to the first 
occurrence of a study outcome or censoring event. We conduced sensitivity analyses to assess the 
robustness of our primary study findings. First, since beta blocker therapy is typically titrated at 2- 
to 4-week intervals, we repeated primary analyses to and restricted the study cohort to only include 
patients with an index beta blocker fill with a days supply of 30 days or less. Second, since 




coverage receive prescription medications at very little or no cost, these individuals may be likely 
to obtain medications without using their prescription insurance benefit. Thus, we repeated 
primary analyses in the subset of study patients with the low-income subsidy benefit. 
 
Results 
Study cohort characteristics 
Figure 5.2 displays a flow diagram of study cohort selection. A total of 26,071 
hemodialysis patients were included in the study. During the 180-day exposure assessment period 
the study cohort filled a total of 98,130 beta blocker prescriptions. A total of 13,476 (51.7%) 
individuals were admitted to the hospital for at least 1 exposure period day, and 2,554 (9.8%) 
individuals received care in a skilled nursing facility for least 1 exposure period day. Of the 98,130 
exposure period beta blocker fills, 19,882 (20.2%) overlapped with a hospital and/or skilled 
nursing facility admission, impacting 11,282 (43.3%) of study hemodialysis patients. When PDC 
was computed using standard methods, the average beta blocker PDC in the study cohort was 
63.9% ± 29.5%, and 10,324 (39.6%) of study patients were classified as adherent to beta blocker 
therapy (PDC ≥ 80%). In contrast, when PDC was computed using modified methods, the average 
beta blocker PDC in the study cohort was 65.8% ± 29.6%, and 11,015 (42.3%) of study patients 
were considered adherent to beta blocker therapy. Table 5.1 displays the study cohort 
characteristics stratified by beta blocker adherence status (PDC ≥ 80% and < 80%).  
Primary analyses 
The study cohort was followed for a total of 20,639 person-years. During follow-up, a total 
of 3,855 all-cause deaths occurred. Regardless of the PDC metric used, patients who were adherent 




individuals who were non-adherent to beta blocker therapy (PDC < 80%). However, when PDC 
was estimated using modified methods (as compared to standard methods) the estimated beta 
blocker adherence-mortality association was attenuated (Table 5.2). 
Sensitivity analyses 
Sensitivity analyses restricting the analytic cohort to individuals that had an index beta 
blocker fill with a days supply of 30 days or less generated results similar to primary analyses. 
Beta blocker adherence (versus non-adherence) was associated with lower all-cause mortality. 
This association was attenuated when adherence was estimated using modified (versus standard) 
PDC (Table 5.3). 
Sensitivity analyses evaluating the beta blocker adherence-mortality association among 
individuals with the Medicare Part D low-income subsidy benefit, also produced results similar 
results to primary analyses. Beta blocker adherence (versus non-adherence) was associated with 
lower all-cause mortality. This association was attenuated when adherence was estimated using 
modified (versus standard) PDC (Table 5.4). 
 
Discussion 
In this study we evaluated the association between beta blocker adherence and all-cause 
mortality in a cohort of maintenance hemodialysis patients. Beta blocker adherence was estimated 
using a common claims-based adherence metric, the PDC. PDC was computed using two different 
approaches: 1) the standard method (using pharmacy claims only), and 2) a modified method 
(using pharmacy claims and also accounting for the time patients spent in the hospital or a skilled 
nursing facility). Under both approaches, we found that patients who were adherent to beta blocker 
therapy (PDC > 80%) as compared to those who were non-adherent (PDC < 80%) had lower rates 




classify patients as adherent or non-adherent, the observed adherence—mortality association was 
attenuated. 
Individuals receiving maintained hemodialysis are at high risk for medication non-
adherence, due to their tremendous comorbid disease burden which requires treatment with an 
average of 10 chronic disease medications.83 Thus, accurate estimates of the longitudinal patterns 
of medication use across time are essential when studying medication adherence in this vulnerable 
patient population. To our knowledge, this is the first investigation describing medication 
adherence in the hemodialysis population using both standard PDC metrics and an alternative 
PDC-based approach that accounted for time spent in the hospital or in a skilled nursing facility. 
In particular, we studied beta blockers, the cardiovascular medication class most commonly 
prescribed to hemodialysis patients.5, 28  When calculating the modified version of the PDC metric, 
we assumed that: 1) beta blockers were provided to patients by hospital inpatient or skilled nursing 
facility pharmacies; and 2) home medication supplies obtained from Medicare Part D-based 
prescription fills were not utilized during these health care encounters and accumulated for later 
use after hospital or skilled nursing facility discharge. The proportion of patients considered as 
adherent to beta blocker therapy (PDC ≥ 80%) was lower when the standard PDC metric was 
employed, indicating that the classification of patients into adherent and non-adherent categories 
varies depending on the PDC metric used to estimate adherence status. Thus, future studies 
describing medication adherence and its subsequent clinical sequelae in the hemodialysis 
population may need to consider multiple adherence assessment approaches to ensure that study 
findings are robust. 
Our results should be considered in the context of study limitations. First, our study was 




data only capture pharmacy-based medication fills that were billed to a patient’s prescription drug 
insurance. Thus, we were unable to identify beta blocker fills that were obtained outside of the 
prescription drug benefit (i.e. cash prescriptions). To address this limitation, we restricted our study 
cohort to patients with Medicare Part D low-income subsidy benefit in sensitivity analyses. These 
individuals receive prescription medications at very little or no cost and are less likely to obtain 
prescription medications from the pharmacy using other payment methods. Reassuringly, the 
observed study findings from this sensitivity analysis were consistent with our primary results. 
Third, the dispensation of a beta blocker prescription does not guarantee that individuals are taking 
the medication. Data on consumption of medications are not available in prescription claims data. 
However, it is reasonable to assume that patients would not continue to fill and pay for prescription 
medications if they are not taking them regularly. Finally, we did not have information provider-
based dosing and discontinuation instructions. Thus, we were not able to differentiate between a 
lack of adherence due beta blocker discontinuation by indication (i.e. the patient experienced a 
side effect warranting therapy cessation) versus self-discontinuation.  
Based on the findings of this study, we conclude that adherence to beta blocker therapy is 
associated with lower all-cause mortality. In addition, our results suggest that it may be important 
to consider time periods spent in the hospital or a skilled nursing facility when computing PDC to 
evaluate the study medication adherence—mortality associations in populations that experience 
high rates of the aforementioned health care admissions (e.g. hemodialysis patients). Further 
research evaluating the impact of the PDC-based adherence adjustment method used in this study 








Table 5.1 Baseline characteristics by beta blocker adherence category 
 Standard PDC  Modified PDC 
Characteristic 
PDC ≥ 80% 
n =10,324 
PDC < 80% 
n = 15,747 
 
PDC ≥ 80% 
n = 11,015 
PDC < 80% 
n = 15,056 
Age (years) 59.2 ±14.7 57.3 ± 14.9  59.4 ±14.7 57.1 ± 14.9 
Female 4,883 (47.3%) 7,307 (46.4%)  5,263 (47.8%) 6,927 (46.0%) 
Race      
   White 5,395 (52.3%) 7,324 (46.5%)  5,737 (52.1%) 6,982 (46.4%) 
   Black 4,315 (41.8%) 7,550 (47.9%)  4,633 (42.1%) 7,232 (48.0%) 
   Other 614 (5.9%) 873 (5.5%)  645 (5.9%) 842 (5.6%) 
Hispanic ethnicity 2,110 (20.4%) 3,086 (19.6%)  2,207 (20.0%) 2,989 (19.9%) 
Low-income subsidy 8,186 (79.3%) 12,275 (78.0%)  8,769 (79.6%) 11,692 (77.7%) 
Year index beta blocker was 
prescribed 
     
   2007 1,644 (15.9%) 3,450 (21.9%)  1,789 (16.2%) 3,305 (22.0%) 
   2008 1,738 (16.8%) 2,979 (18.9%)  1,865 (16.9%) 2,852 (18.9%) 
   2009 1,649 (16.0%) 2,595 (16.5%)  1,768 (16.1%) 2,476 (16.4%) 
   2010 1,896 (18.4%) 2,566 (16.3%)  2,010 (18.2%) 2,452 (16.3%) 
   2011 2,170 (21.0%) 2,675 (17.0%)  2,289 (20.8%) 2,556 (17.0%) 
   2012 1,227 (11.9%) 1,482 (9.4%)  1,294 (11.7%) 1,415 (9.4%) 
Cause of ESRD      
   Diabetes 4,921 (47.7%) 7,134 (45.3%)  5,327 (48.4%) 6,728 (44.7%) 
   Hypertension 2,967 (28.7%) 4,652 (29.5%)  3,135 (28.5%) 4,484 (29.8%) 
   Glomerular disease 1,125 (10.9%) 1,891 (12.0%)  1,180 (10.7%) 1,836 (12.2%) 
   Other 1,311 (12.7%) 2,070 (13.1%)  1,373 (12.5%) 2,008 (13.3%) 
Body mass index        
   < 18.5 kg/m2 417 (4.0%) 710 (4.5%)  459 (4.2%) 668 (4.4%) 
   18.5 – 24.9 kg/m2 3,788 (36.7%) 5,689 (36.1%)  4,065 (36.9%) 5,412 (35.9%) 
   25.0 – 29.9 kg/m2 2,980 (28.9%) 4,552 (28.9%)  3,158 (28.7%) 4,374 (29.1%) 
   ≥ 30.0 kg/m2 3,139 (30.4%) 4,796 (30.5%)  3,333 (30.3%) 4,602 (30.6%) 
History of prior renal 
transplant 
668 (6.5%) 1,218 (7.7%)  700 (6.4%) 1,186 (7.9%) 
Dialysis vintage      
   < 1.0 year 644 (6.2%) 848 (5.4%)  683 (6.2%) 809 (5.4%) 
   1.0 – 1.9 years 2,301 (22.3%) 3,184 (20.2%)  2,463 (22.4%) 3,022 (20.1%) 
   2.0 – 2.9 years 1,702 (16.5%) 2,530 (16.1%)  1,803 (16.4%) 2,429 (16.1%) 
   ≥ 3.0 years 5,677 (55.0%) 9,185 (58.3%)  6,066 (55.1%) 8,796 (58.4%) 
Atrial fibrillation 1,131 (11.0%) 1,623 (10.3%)  1,271 (11.5%) 1,483 (9.8%) 
Other arrhythmia 791 (7.7%) 1,179 (7.5%)  881 (8.0%) 1,089 (7.2%) 
Angina 155 (1.5%) 272 (1.7%)  175 (1.6%) 252 (1.7%) 
Cancer    311 (3.0%) 442 (2.8%)  335 (3.0%) 418 (2.8%) 
Conduction disorder 260 (2.5%) 396 (2.5%)  292 (2.7%) 364 (2.4%) 
COPD/asthma 1,433 (13.9%) 2,239 (14.2%)  1,597 (14.5%) 2,075 (13.8%) 




Diabetes 5,226 (50.6%) 7,651 (48.6%)  5,714 (51.9%) 7,163 (47.6%) 
GI bleed    441 (4.3%) 748 (4.8%)  500 (4.5%) 689 (4.6%) 
Heart failure    2,920 (28.3%) 4,724 (30.0%)  3,253 (29.5%) 4,391 (29.2%) 
Hypertension 7,088 (68.7%) 11,055 (70.2%)  7,705 (70.0%) 10,438 (69.3%) 
Liver disease 386 (3.7%) 728 (4.6%)  425 (3.9%) 689 (4.6%) 
Myocardial infarction 522 (5.1%) 767 (4.9%)  575 (5.2%) 714 (4.7%) 
Peripheral artery disease 1,861 (18.0%) 2,952 (18.7%)  2,111 (19.2%) 2,702 (17.9%) 
Stroke 1,031 (10.0%) 1,343 (8.5%)  1,178 (10.7%) 1,196 (7.9%) 
Valvular disease 661 (6.4%) 1,082 (6.9%)  737 (6.7%) 1,006 (6.7%) 
History of non-compliancea 452 (4.4%) 919 (5.8%)  512 (4.6%) 859 (5.7%) 
Vascular access      
   Fistula 6,171 (59.8%) 9,059 (57.5%)  6,491 (58.9%) 8,739 (58.0%) 
   Graft 2,703 (26.2%) 4,133 (26.2%)  2,880 (26.1%) 3,956 (26.3%) 
   Catheter 1,450 (14.0%) 2,555 (16.2%)  1,644 (14.9%) 2,361 (15.7%) 
Interdialytic weight gain  
≥ 3 kg   
2,491 (24.1%) 4,187 (26.6%)  2,650 (24.1%) 4,02 (26.8%) 
Delivered dialysis treatment 
time < 240 min 
8.222 (79.6%) 12,397 (78.7  8,776 (79.7%) 11,843 (78.7%) 
Pre-dialysis systolic BP      
   < 130 mmHg  1,019 (9.9%) 1,703 (10.8%)  1,107 (10.0%) 1,615 (10.7%) 
   130 – 149 mmHg 2,805 (27.2%) 4,019 (25.5%)  2,999 (27.2%) 3,825 (25.4%) 
   150 – 169 mmHg 3,710 (35.9%) 5,607 (35.6%)  3,949 (35.9%) 5,368 (35.7%) 
   ≥170 mmHg 2,790 (27.0%) 4,418 (28.1%)  2,960 (26.9%) 4,248 (28.2%) 
Recent history of 
intradialytic hypotensionb 
1,075 (10.4%) 1,907 (12.1%)  1,179 (10.7%) 1,803 (12.0%) 
Albumin         
   ≤ 3.0 g/dL 363 (3.5%) 561 (3.6%)  440 (4.0%) 484 (3.2%) 
   3.1 – 4.0 g/dL   6,255 (60.6%) 9,842 (62.5%)  6,731 (61.1%) 9,366 (62.2%) 
   > 4.0 g/dL 3,706 (35.9%) 5,344 (33.9%)  3,844 (34.9%) 5,206 (34.6%) 
Calcium          
   < 8.5 mg/dL 1,428 (13.8%) 2,436 (15.5%)  1,506 (13.7%) 2,358 (15.7%) 
   8.5 – 10.2 mg/dL 8,488 (82.2%) 12,488 (79.3%)  9,048 (82.1%) 11,928 (79.2%) 
   > 10.2 mg/dL 408 (4.0%) 823 (5.2%)  461 (4.2%) 770 (5.1%) 
Phosphorus      
   < 3.5 mg/dL 1,146 (11.1%) 1,480 (9.4%)  1,237 (11.2%) 1,389 (9.2%) 
   3.5 – 5.5 mg/dL 5,887 (57.0%) 8,001 (50.8%)  6,272 (56.9%) 7,616 (50.6%) 
   > 5.5 mg/dL 3,291 (31.9%) 6,266 (39.8%)  3,506 (31.8%) 6,051 (40.2%) 
Potassium      
   < 4.0 mEq/L 1,078 (10.4%) 1,711 (10.9%)  1,149 (10.4%) 1,640 (10.9%) 
   4.0 – 6.0 mEq/L 8,872 (85.9%) 13,422 (85.2%)  9,453 (85.8%) 12,841 (85.3%) 
   > 6.0 mEq/L 374 (3.6%) 614 (3.9%)  413 (3.7%) 575 (3.8%) 
Hemoglobin         
   < 9.5 g/dL 600 (5.8%) 908 (5.8%)  664 (6.0%) 844 (5.6%) 
   9.5 – 12.0 mg/dL 6,510 (63.1%) 9,198 (58.4%)  6,914 (62.8%) 8,794 (58.4%) 
   > 12.0 mg/dL 3,214 (31.1%) 5,641 (35.8%)  3,437 (31.2%) 5,418 (36.0%) 




Number of medications in 
last 30 days of baseline 
5.9 ± 3.9 5.0 ± 3.7  6.0 ± 3.9 5.0 ± 3.7 
Alpha blocker 101 (1.0%) 125 (0.8%)  108 (1.0%) 118 (0.8%) 
ACE inhibitor 2,847 (27.6%) 3,371 (21.4%)  3,002 (27.3%) 3,216 (21.4%) 
Angiotensin receptor 
blocker 
1,451 (14.1%) 1,589 (10.1%)  1,514 (13.7%) 1,526 (10.1%) 
Calcium channel blocker 4,131 (40.0%) 4,979 (31.6%)  4,348 (39.5%) 4,762 (31.6%) 
Central alpha agonist 1,762 (17.1%) 2,279 (14.5%)  1,874 (17.0%) 2,167 (14.4%) 
Diuretic 1,324 (12.8%) 1,469 (9.3%)  1,399 (12.7%) 1,394 (9.3%) 
Vasodilator 1,344 (13.0%) 1,599 (10.2%)  1,414 (12.8%) 1,529 (10.2%) 
Statin 3,079 (29.8%) 3,394 (21.6%)  3,257 (29.6%) 3,216 (21.4%) 
Other cholesterol 
medicationc 
485 (4.7%) 547 (3.5%)  518 (4.7%) 514 (3.4%) 
Digoxin 200 (1.9%) 285 (1.8%)  224 (2.0%) 261 (1.7%) 
Long-acting nitrate 808 (7.8%) 959 (6.1%)  871 (7.9%) 896 (6.0%) 
Antiplatelet medication 1,315 (12.7%) 1,652 (10.5%)  1,413 (12.8%) 1,554 (10.3%) 
Anticoagulant medication 784 (7.6%) 1,087 (6.9%)  856 (7.8%) 1,015 (6.7%) 
Midodrine 159 (1.5%) 239 (1.5%)  175 (1.6%) 223 (1.5%) 
All-covariates were measured during the baseline period prior to beta block initiation. Values are given as number 
(%) for categorical variables and as mean ± standard deviation for continuous variables.  
 
 
a Claims-based definition of non-compliance included ICD-9 discharge diagnosis codes V15.81 (personal history of 
noncompliance with medical treatment, presenting hazards to health) and V45.12 (noncompliance with renal dialysis). 
 
b Patients were considered as having a recent history of intradialytic hypotension if they had an intradialytic nadir 
systolic blood pressure < 90 mmHg in at least 30% of outpatient hemodialysis treatments in the last 30 days of the 
baseline period.57 
 
c Other cholesterol medications included the following non-statin cholesterol medications: bile acid sequestrants, 
cholesterol absorption inhibitors, fibrates and niacin.  
 
Abbreviations: ACE, angiotensin converting enzyme; BP, blood pressure; COPD, chronic obstructive pulmonary 



















Table 5.2 Association between beta blocker adherence versus non-adherence and 1-year 
mortality 






HR (95% CI) 
Adjusted 
HR (95% CI) 
Standard PDC      
   PDC < 80% (non-adherent) 15,747 2,449 (15.6%) 19.6 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 10,324 1,406 (13.6%) 17.3 0.88 (0.83, 0.94) 0.84 (0.79, 0.90) 
      
Modified PDC      
   PDC < 80% (non-adherent) 15, 056 2,234 (14.8%) 18.6 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 11,015 1,621 (14.7%) 18.7 1.01 (0.94, 1.08) 0.91 (0.85, 0.97) 
A total of 26,071 hemodialysis patients were included in the full study cohort. Multivariable Cox proportional hazards 
models, adjusting for baseline covariates specified in Table 5.1, were used to estimate the associations beta blocker 
adherence versus non-adherence blocker adherence and 1-year all-cause mortality.  
 





































Table 5.3 Association between beta blocker adherence versus non-adherence and 1-year 
mortality among individuals who filled an index beta blocker with a days supply of ≤ 30 
days 






HR (95% CI) 
Adjusted 
HR (95% CI) 
Standard PDC      
   PDC < 80% (non-adherent) 13,490 2,111 (15.7%) 19.6 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 8.004 1,170 (13.8%) 18.4 0.89 (0.82, 0.95) 0.83 (0.78, 0.90) 
      
Modified PDC      
   PDC < 80% (non-adherent) 12,878 1,917 (14.9%) 18.6 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 8,616 1,301 (15.1%) 19.1 1.03 (0.96, 1.10) 0.91 (0.85, 0.98) 
A total of 21,949 hemodialysis patients filled an index beta blocker with a days supply ≤ 30 days. Multivariable Cox 
proportional hazards models, adjusting for baseline covariates specified in Table 5.1, were used to estimate the 
associations beta blocker adherence versus non-adherence blocker adherence and 1-year all-cause mortality.  
 




































Table 5.4 Association between beta blocker adherence versus non-adherence and 1-year 
mortality among patients with the low-income subsidy benefit 






HR (95% CI) 
Adjusted 
HR (95% CI) 
Standard PDC      
   PDC < 80% (non-adherent) 12,275 1,792 (14.6%) 18.1 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 8,186 1,037 (12.7%) 15.9 0.88 (0.81, 0.95) 0.84 (0.78, 0.91) 
      
Modified PDC      
   PDC < 80% (non-adherent) 11,692 1,611 (13.8%) 17.0 1.00 (ref.) 1.00 (ref.) 
   PDC ≥ 80% (adherent) 8,769 1,218 (13.9%) 17.6 1.03 (0.96, 1.11) 0.93 (0.86, 1.00) 
A total of 20,461 hemodialysis patients had the low-income subsidy benefit. Multivariable Cox proportional hazards 
models, adjusting for baseline covariates specified in Table 5.1, were used to estimate the associations beta blocker 
adherence versus non-adherence blocker adherence and 1-year all-cause mortality.  
 




























Figure 5.2 Illustration of beta blocker days supply adjustment made when patients were 
admitted to the hospital or skilled nursing facility in Aim 2 analyses 
 
 





















CHAPTER 6: RESULTS AIM 3 
Introduction 
Individuals receiving maintenance hemodialysis have cardiovascular mortality rates that 
exceed those of the general population by 5 to 7-fold.1 Cardioprotective medications such as beta 
blockers, among others, are often prescribed to reduce cardiovascular risk. However, clinical trials 
establishing the cardioprotective nature and safety of beta blockers largely excluded individuals 
with ESRD.2, 3Approximately 65% of the U.S. hemodialysis population is treated with a beta 
blocker.5 Despite widespread use, surprisingly little is known about the relative safety and efficacy 
of different beta blockers in hemodialysis patients, a population with special drug dosing 
considerations.  
Within the beta blocker class, individual medications possess different pharmacologic and 
pharmacokinetic properties. Pharmacologically, beta blockers differ with respect to their beta-
adrenergic receptor selectivity and vasodilatory capabilities. Kinetically, physiochemical factors, 
such as molecular size, hydrophilicity, plasma-protein binding, and volume of distribution 
influence the extent of beta blocker clearance by the hemodialysis procedure (i.e. dialyzablity). 
These key differences may plausibly alter the hemodynamic and antiarrhythmic risk-benefit 
profiles of individual beta blockers in the setting of ESRD. 
In fact, observational data suggests that the potential survival benefit conferred by beta 
blockers may differ across agents. In a Canadian cohort, Weir et al. found that the risk of all-cause 
death was significantly higher among hemodialysis patients treated with high dialyzablity beta 




dialyzablity beta blockers (bisoprolol and propranolol).46 However, carvedilol and metoprolol 
succinate, two commonly prescribed beta blockers in the U.S.,5 were not considered due to 
provincial prescription formulary restrictions. Carvedilol is a non-selective beta blocker with 
additional alpha-blocking effects and is minimally cleared by hemodialysis. Metoprolol (tartrate 
and succinate) is a cardioselective beta blocker and is extensively cleared by hemodialysis. The 
marked pharmacologic and pharmacokinetic heterogeneity between carvedilol and metoprolol 
may differentially influence clinical outcomes and safety among individuals receiving 
maintenance hemodialysis and warrants further study. 
While a head-to-head randomized clinical trial would be the ideal approach to investigating 
the comparative safety and efficacy of carvedilol and metoprolol in the dialysis population, a recent 
feasibility study suggested that recruitment for such a trial may be challenging.45 Well-designed 
pharmacoepidemiologic studies are thus needed to inform clinical decision-making. We undertook 
this study to investigate the association between carvedilol versus metoprolol initiation and 1-year 
mortality in a cohort of prevalent, maintenance in-center hemodialysis patients treated by a large 




The study data were extracted from the clinical database of a large U. S. dialysis 
organization and the USRDS. Data were linked at the patient level. The dialysis organization 
operates over 1,500 outpatient dialysis clinics throughout the nation. Its database captures detailed 
demographic, clinical, laboratory, and dialysis treatment data. Laboratory data are measured on a 




treatment basis. The USRDS is a national ESRD surveillance system that includes: the Medical 
Evidence and ESRD Death Notification forms, the Medicare Enrollment database (a repository of 
Medicare beneficiary enrollment and entitlement data), and Medicare standard analytic files (final 
action administrative claims data including Medicare Parts A, B and D). 
Study design and population 
We conducted a retrospective cohort study using a new-user design77 to investigate the 
association between carvedilol versus metoprolol initiation and 1-year all-cause and 
cardiovascular mortality (separately) among individuals receiving maintenance hemodialysis. 
Figure 6.1 displays the study design. First, using Medicare Part D claims, we identified dialysis 
patients treated at the large dialysis organization who initiated oral beta blocker therapy from 
January 1, 2007 to December 30, 2012 following a 180-day washout period free of any 
documented oral beta blocker use. We then applied the following exclusion criteria: 1) age < 18 
years old at the start of the baseline period, 2) dialysis vintage ≤ 90 days at the start of the baseline 
period, 3) lack of continuous Medicare Part A, B and D coverage during the baseline period, 4) 
receipt of home hemodialysis or peritoneal dialysis during the baseline period, 5) receipt of < 6 
center-based hemodialysis treatments in the last 30 days of the baseline period, 6) receipt of 
hospice care during the baseline period, 7) missing demographic or laboratory data, and 8) 
initiation of a beta blocker other than carvedilol or metoprolol. Thus, the study cohort consisted of 
prevalent, adult hemodialysis patients who were carvedilol or metoprolol new-users. 
Exposure, outcomes, and censoring events 
The exposures of interest were carvedilol and metoprolol initiation. The index date was 
designated as the date of the first carvedilol or metoprolol prescription after the washout period. 




separately). Cardiovascular mortality was defined using the USRDS definition (Table 6.1).84 
Individuals were followed forward in historical time from the index date to the first occurrence of 
a study outcome or censoring event. Censoring events included: kidney transplantation, dialysis 
modality change, recovery of renal function, loss of Medicare Part A, B or D coverage, being lost 
to follow-up, reaching 1-year of follow-up post-index date, or study end (December 31, 2012).  
Baseline covariate determination 
Baseline covariates included potential confounders and variables known to be strong risk 
factors for death in the hemodialysis population.85 Covariates were identified in the 180 days prior 
to the index date and included: patient demographics, comorbid conditions, laboratory data, 
dialysis treatment parameters, and prescription medication use (Appendix: Supplemental Table 
1).  
Statistical analysis 
Baseline characteristics are described across carvedilol and metoprolol initiators as count 
(%) for categorical variables and mean ± standard deviation for continuous variables. Baseline 
covariate distributions were compared using standardized differences. A standardized difference 
>0.1 represents meaningful imbalance between treatment groups.80 
In primary analyses, we used an intent-to-treat approach to evaluate the association 
between carvedilol (versus metoprolol) initiation and 1-year all-cause and cardiovascular 
mortality. Cox proportional hazards models were used to assess the study medication—all-cause 
mortality association.  Fine and Gray proportional subdistribution hazards models81 that treated 
non-cardiovascular death as a competing risk were used to assess the study medication—
cardiovascular mortality association.  Both models estimate HRs and their 95% CIs. IPT weighting 




predicted probability (i.e. propensity score) of receiving carvedilol (versus metoprolol) as a 
function of baseline covariates. Propensity scores were used to generate IPT weights.82 We 
estimated adjusted HRs by applying IPT weights in regression models. 
In secondary analyses, using methods analogous to primary analyses, we assessed the 
association between carvedilol (versus metoprolol) initiation and 1-year morality in clinically 
relevant subgroups including individuals with hypertension, atrial fibrillation, heart failure and 
myocardial infraction, the main cardiovascular indications for beta blocker therapy.  
We conducted several sensitivity analyses to assess the robustness of our primary results. 
First, since the effect of metoprolol (versus carvedilol) on all-cause mortality may differ by 
metoprolol formulation,86 we repeated primary analyses and separately compared: 1) carvedilol 
versus metoprolol tartrate (the immediate release formulation), and 2) carvedilol versus metoprolol 
succinate (the controlled/extended release formulation).  Second, since beta blocker therapy is 
typically titrated, we repeated primary analyses restricted the cohort to patients who initiated on 
low doses carvedilol (≤ 25 mg) or metoprolol (≤ 100 mg). Third, since Medicare Part D 
beneficiaries who have supplemental low-income subsidy coverage receive prescription 
medications at very little or no cost, these individuals are less likely to obtain medications without 
using their prescription insurance benefit. We thus repeated, primary analyses in the subset of 
study patients with the low-income subsidy benefit. Fourth, we repeated primary analyses using 
an on-treatment (i.e. per-protocol) approach. In these analyses, index beta blocker discontinuation 
and switching to a non-index beta blocker during follow-up were considered additional censoring 
events. A discontinuation event occurred when the days supply of the index beta blocker 
medication was exhausted for > 60 days (a grace/gap period to allow for imperfect adherence) 




discontinuation date. was Beta blocker medication days supply were adjusted for hospital and 
skilled nursing facility admissions. Fifth, we tested the specificity of our findings by examining 
the association between carvedilol (versus metoprolol) initiation and hospitalized bowel 
obstruction, a tracer (i.e. negative control) outcome that we did not expect to be influenced by the 
utilization of either of the study medications. 
Finally, we conducted additional post hoc analyses to evaluate potential mechanistic 
explanations for our study findings. We assessed the association between carvedilol (versus 
metoprolol) initiation and the occurrence of intradialytic hypotension by estimating incidence rate 
ratios (IRRs) and their 95% CIs using Poisson regression. Episodes of intradialytic hypotension 
were identified using two different definitions: 1) a systolic blood pressure decline ≥ 20 mmHg 
during dialysis accompanied by saline administration (a guideline-based definition);87-89 and 2) an 
intradialytic nadir systolic blood pressure < 90 mmHg (a definition shown to associate with 
mortality).57   
 
Results 
Study cohort characteristics 
Figure 6.2 displays a flow diagram of study cohort selection. A total of 27,064 individuals 
receiving maintenance hemodialysis were included in the study: 9,558 (35.3%) carvedilol initiators 
and 17,506 (64.7%) metoprolol initiators. Overall, study patients had an average age of 59.6 ± 14.7 
years, 46.7% were female, 42.9% were black, 19.5% were Hispanic and the most common ESRD 
cause was diabetes (49.0%). Cardiovascular comorbidities were common; 13.9% of the cohort had 
atrial fibrillation, 29.9% had coronary atherosclerosis, 72.7% had hypertension, 34.6% had heart 




The propensity score distribution of carvedilol and metoprolol initiators exhibited 
substantial overlap (Figure 6.3), indicating that the study groups were highly comparable. Patient 
baseline characteristics stratified by study beta blocker are presented in Table 6.2. Before IPT 
weighting, baseline covariates were generally well-balanced between treatment groups 
(standardized differences ≤ 0.1), with a few exceptions (year of index carvedilol or metoprolol 
initiation, heart failure and an ESRD cause of diabetes). After IPT weighting all baseline covariates 
were well-balanced between treatment groups.  
Primary analyses 
 Under the intent-to-treat paradigm, the study cohort was followed for a total of 20,863 
person-years (7,219 person-years for carvedilol initiators and 13,644 metoprolol initiators). The 
average duration of follow-up was 275 days for carvedilol initiators and 285 days for metoprolol 
initiators. During follow-up 4,296 all-cause deaths (1,625 in the carvedilol group and 2,671 in the 
metoprolol group) and 1,943 cardiovascular deaths (782 in the carvedilol group and 1,161 in the 
metoprolol group) occurred.  Figure 6.4 displays the associations between carvedilol (versus 
metoprolol) initiation and 1-year all-cause and cardiovascular mortality. Compared to individuals 
initiating metoprolol, individuals initiating carvedilol had a higher rate of all-cause mortality 
(225.1 versus 195.8 events/1,000 person-years; adjusted HR [95% CI] = 1.09 [1.02, 1.16]) and 
cardiovascular mortality (108.3 versus 85.1 events/100 person-years; adjusted HR [95% CI] = 1.19 
[1.08, 1.30]).  
Secondary analyses 
Secondary analyses assessing associations between carvedilol (versus metoprolol) 
initiation and mortality among individuals with hypertension, atrial fibrillation, heart failure or a 





Sensitivity analyses comparing carvedilol initiators to metoprolol tartrate and metoprolol 
succinate initiators (separately) generated results similar to primary analyses. Treatment with 
carvedilol (versus metoprolol) was associated increased 1-year all-cause and cardiovascular 
mortality, regardless of the comparator metoprolol formulation (Table 6.4). In addition, separate 
sensitivity analyses restricting the study cohort to 1) individuals who initiated a low-dose study 
beta blocker, and 2) patients with the Medicare Part D low-income subsidy benefit, also produced 
results similar results to primary analyses (Tables 6.5 and 6.6). 
In sensitivity analyses using an on-treatment paradigm, the study cohort was followed for 
a total of 14,460 person-years (5,127 person-years for carvedilol-treated patients and 9,333 person-
years for metoprolol-treated patients). During follow-up there were 2,941 all-cause deaths (1,117 
in the carvedilol group and 1,824 in the metoprolol group) and 1,341 cardiovascular deaths (544 
in the carvedilol group and 797 in the metoprolol group) occurred. A total of 11,110 individuals 
discontinued index beta blocker therapy and 1,662 switched to a different beta blocker during 
follow-up. The average duration of continuous index medication use was 195 days for both 
carvedilol initiators metoprolol initiators. Individuals who remained on carvedilol (versus 
metoprolol) treatment trended toward higher rates of all-cause mortality (217.9 versus 195.4 
events/1,000 person-years; adjusted HR [95% CI] = 1.06 [0.98, 1.14]) and had higher rates 
cardiovascular mortality (106.1 versus 85.4 events/1,000 person-years; adjusted HR [95% CI] = 
1.15 [1.03, 1.29]).  
In sensitivity analyses evaluating the study medication—tracer outcome association, 




bowel obstruction (rate of 30.3 versus 28.7 events/1,000 person-years; adjusted HR [95% CI] = 
1.02 [0.86, 1.20]). 
Post hoc analyses 
The rate of intradialytic hypotension (systolic BP decline ≥ 20 mmHg during hemodialysis 
accompanied by saline administration) during study follow-up was higher among carvedilol 
(versus metoprolol) initiators (57.5 versus 55.2 episodes/1,000 person-treatments; adjusted IRR 
[95% CI] = 1.10 [1.09, 1.11]). Similar findings were observed when an episode of intradialytic 
hypotension was defined as an intradialytic nadir systolic blood pressure < 90 mmHg (comparing 
carvedilol to metoprolol initiators: rate of 144.4 versus 136.5 episodes/1,000-person-treatments; 
adjusted IRR [95% CI] = 1.02 [1.01, 1.03] comparing carvedilol to metoprolol initiators).  
 
Discussion 
To our knowledge, this is the first published study evaluating the comparative mortality 
risk of carvedilol and metoprolol among individuals receiving maintenance hemodialysis. We 
demonstrated that carvedilol (versus metoprolol) initiation was associated with increased 1-year 
all-cause and cardiovascular mortality. The associations were consistent within clinically relevant 
subgroups and robust across sensitivity analyses. We also found that carvedilol initiators 
experienced significantly higher rates of intradialytic hypotension compared to metoprolol 
initiators.  
To date, there have been no randomized clinical trials comparing the efficacy and safety of 
individual beta blockers in the dialysis population. Prior beta blocker clinical trials were either 
placebo-controlled23, 45 or compared beta blockers to other antihypertensive classes (e.g. 




predominantly focused on comparing beta blocker users to non-users,16, 66, 68, 69, 72-74 and only two 
observational studies considered head-to-head beta blocker comparisons. Weir et al. assessed the 
association between beta blocker dialyzability and 180-day mortality in a cohort of 6,588 elderly, 
Canadian hemodialysis patients.46 Initiation of a highly dialyzable beta blocker versus a 
minimally-dialyzable beta blocker was associated with increased all-cause death. This study 
provided initial evidence that beta blocker heterogeneity may differentially impact clinical 
outcomes in the hemodialysis population, but, carvedilol (a minimally dialyzable beta blocker) 
and metoprolol succinate (a highly dialyzable beta blocker) were not considered. In the U.S., 
carvedilol and metoprolol succinate account for 50% of all beta blocker prescriptions.  
In a second epidemiologic study, Shireman et al. evaluated the association between beta 
blocker selectivity and mortality in a cohort of 4,398 incident U.S. hemodialysis and peritoneal 
dialysis patients with dual Medicare/Medicaid coverage and hypertension.47 Initiation of a 
cardioselective beta blocker (atenolol, metoprolol) versus a non-selective beta blocker (carvedilol, 
labetalol) was associated with increased survival. However, the relative contributions of carvedilol 
and metoprolol to the observed association are unclear, and this investigation relied on data from 
2000-2005. In the last decade, carvedilol use has risen,5, 41 rendering a contemporary analysis 
important. In fact, international guideline bodies have called for additional comparative 
effectiveness research on putative cardioprotective drugs such as beta blockers in the hemodialysis 
population.4 
To begin to address this evidence gap, we performed a head-to-head comparison of the two 
most commonly prescribed beta blockers in the U.S., carvedilol and metoprolol. We found that 
carvedilol (versus metoprolol) initiation was associated with higher 1-year all-cause and 




fibrillation, heart failure, and a recent myocardial infarction. Furthermore, the observed study beta 
blocker—mortality association was robust across sensitivity analyses comparing carvedilol to 
immediate-release metoprolol tartrate and extended/controlled-release metoprolol succinate 
(separately). In post hoc analyses, we found that the occurrence of intradialytic hypotension 
(defined two ways) was more common after carvedilol (versus metoprolol) initiation. Given that 
recurrent intradialytic hypotension is associated with increased morbidity and mortality in the 
hemodialysis population,57, 63, 64, 90  the results from our post hoc analyses support the notion that 
hemodynamic instability may play a mechanistic role in the observed association between 
carvedilol (versus metoprolol) initiation and greater mortality.  
Pharmacologic and kinetic differences between carvedilol and metoprolol may plausibly 
explain the observed difference in mortality and intradialytic hypotension occurrence. First, the 
extent to which a beta blocker is removed from circulation by hemodialysis may impact 
intradialytic blood pressure. Carvedilol is minimally dialyzable, and metoprolol is highly 
dialyzable. As a result, carvedilol’s antihypertensive effects are likely maintained over the course 
of dialysis, whereas metoprolol’s blood pressure lowering effects may be diminished as plasma 
drug concentrations fall during treatment. Second, carvedilol and metoprolol differ with respect to 
their beta-adrenergic receptor selectivity and vasodilatory capabilities. Carvedilol is a non-
selective beta blocker (beta-1 and beta-2 adrenergic receptor antagonist) with additional alpha-
blocking (alpha-1 adrenergic receptor antagonist) activity. In contrast, metoprolol is a 
cardioselective beta blocker with high β1 adrenergic receptor affinity. Both medications reduce 
heart rate and cardiac contractility, but due to its alpha-blocking effects, carvedilol is also a 
vasodilator. It is plausible that carvedilol-induced alpha blockade may blunt compensatory 




the risk of intradialytic hemodynamic instability. These proposed clinical mechanisms likely act 
in concert in carvedilol-treated patients. 
Ultimately, randomized controlled clinical trials are needed to definitively determine the 
relative safety and efficacy of carvedilol and metoprolol in the hemodialysis population.  However, 
in the interim, our results suggest that the potential adverse hemodynamic effects of carvedilol 
(versus metoprolol) require consideration when prescribing beta blockers to hemodialysis patients, 
particularly among individuals with a history of intradialytic hemodynamic instability. For 
example, it may be reasonable to: 1) consider metoprolol over carvedilol among individuals at 
higher risk for intradialytic hypotension; or 2) recommend that patients hold carvedilol doses prior 
to hemodialysis treatments to minimize potential intradialytic hypotensive effects. However, such 
decisions must be made carefully on an individual basis with consideration of comorbid 
cardiovascular conditions, historical blood pressure patterns and concomitant antihypertensive 
medication use and dosing. 
Our study has several strengths. First, we used modern pharmacoepidemiologic study 
design to evaluate the comparative mortality risks associated with carvedilol and metoprolol 
treatment. To minimize the influence of bias due to confounding by indication or disease severity, 
we selected study medications with similar indications and therapeutic roles.91 Notably, the 
carvedilol and metoprolol initiators were highly comparable, and all baseline covariate imbalances 
between treatment groups were diminished after IPT weighting. Additionally, we chose to study 
the two most commonly prescribed beta blockers to closely mirror a real-world clinical practice 
decision.91 Second, unlike previous claims-based studies, we utilized a linked data set with detailed 




treatment parameters in our analyses. Finally, we performed multiple sensitivity analyses to test 
the robustness of our findings. 
Our results should be considered in the context of study limitations First, our study was 
observational, and it is possible that residual confounding may exist. To minimize confounding 
from difficult-to-measure factors such as ambient health status, we controlled for variables 
including albumin, phosphorus, and a history of non-compliance. Reassuringly, carvedilol (versus 
metoprolol) initiation was not associated with the occurrence of the tracer outcome, hospitalized 
bowel obstruction. Second, while our linked data source was comprised of detailed administrative 
and clinical data, information on some potentially important factors, such as the timing of 
medication dosing, were not available. Third, comorbid condition designations were based upon 
ICD-9 diagnosis codes. Comorbidities not requiring a healthcare encounter during the 180-day 
baseline period may have been missed. Fourth, our study population was comprised of individuals 
receiving center-based maintenance hemodialysis who initiated carvedilol or metoprolol. Our 
results should not be extrapolated to excluded populations such as home hemodialysis or peritoneal 
dialysis patients, or hemodialysis patients receiving other beta blockers. Finally, our study 
evaluated a cohort of U.S. hemodialysis patients. Our results may not apply to other countries 
where national or regional prescription formularies limit metoprolol and/or carvedilol prescribing. 
In conclusion, we observed that carvedilol (versus metoprolol) initiation was associated 
with higher 1-year all-cause and cardiovascular mortality in a cohort of U.S. hemodialysis patients. 
Data from our post hoc analyses suggest that one potential mechanism for the observed mortality 
associations may be an increased rate of intradialytic hypotension after carvedilol (versus 




ESRD population, additional study of the efficacy and safety of beta blockers, as well as other 


























Table 6.1 Aim 3 Outcome definitions 
Main study outcomes 
Clinical outcome Data source Specification 
All-cause mortality USRDS Patients File Death due to any cause 
Cardiovascular mortality84 USRDS Patients File Death with any cardiovascular death code (23, 25, 26, 27, 28, 
29, 30, 31, 32, 35 or 36) listed as the primary cause of death 
on the ESRD death notification forma 
Tracer outcome 
Clinical outcome Data source Specification 
Hospitalized bowel 
obstruction 
USRDS Medicare Part A Claims Claim for an inpatient hospital admission with a bowel 
obstruction ICD-9 discharge diagnosis code (560) located in 
the any billing positionb 
 a The cardiovascular cause of death codes include the following clinical conditions: acute myocardial infarction, 
pericarditis (including cardiac tamponade), atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac 
arrest (cause unknown), valvular heart disease, pulmonary edema due to exogenous fluid, congestive heart failure, 
pulmonary embolus and cerebrovascular accident (including intracranial hemorrhage).  
 
b Specified three-digit ICD-9 diagnosis code categories included all existing 4th and 5th digit diagnosis codes.  
 
Abbreviations: ESRD, end-stage renal disease; ICD-9, International Classification of Diseases, 9th Revision; USRDS, 

























Table 6.2 Baseline characteristics of study patients initiating carvedilol and metoprolol 
 Unweighted  Weighted 
Characteristic 
Carvedilol 
n = 9,558 
Metoprolol 





n = 9,532 
Metoprolol 
n = 17,522 
Standardized 
differencea 
Age (years) 59.8 ±14.4 59.5 ±14.9 0.026  59.8 ± 14.4 59.5 ± 14.9 0.026 
Female 4,314 (45.1%) 8,316 (47.5%) 0.048  4,444 (46.6%) 8,184 (46.7%) 0.002 
Race        
   White 4,848 (50.7%) 9,054 (51.7%) 0.020  4,880 (51.2%) 8,992 (51.3%) 0.002 
   Black 4,186 (43.8%) 7,419 (42.4%) 0.029  4,102 (43.0%) 7,525 (42.9%) 0.002 
   Other 524 (5.5%) 1,033 (5.9%) 0.018  549 (5.8%) 1,006 (5.7%) 0.001 
Hispanic ethnicity 1,925 (20.1%) 3,351 (19.1%) 0.025  1,867 (19.6%) 3,420 (19.5%) 0.002 
Low-income subsidy 7,259 (75.9%) 13,524 (77.3%) 0.031  7,326 (76.9%) 13,463 (76.8%) 0.001 
Year index beta blocker was 
prescribed 
       
   2007 1,339 (14.0%) 3,364 (19.2%) 0.140  1,632 (17.1%) 3,035 (17.3%) 0.005 
   2008 1,385 (14.5%) 3,011 (17.2%) 0.074  1,534 (16.1%) 2,834 (16.2%) 0.002 
   2009 1,440 (15.1%) 2,561 (14.6%) 0.012  1,405 (14.7%) 2,588 (14.8%) 0.001 
   2010 1,524 (15.9%) 2,696 (15.4%) 0.015  1,495 (15.7%) 2,734 (15.6%) 0.002 
   2011 1,804 (18.9%) 2,852 (16.3%) 0.068  1,664 (17.5%) 3,029 (17.3%) 0.005 
   2012 2,066 (21.6%) 3,022 (17.3%) 0.110  1,801 (18.9%) 3,303 (18.9%) 0.001 
Cause of ESRD        
   Diabetes 5,027 (52.6%) 8,227 (47.0%) 0.112  4,703 (49.3%) 8,607 (49.1%) 0.004 
   Hypertension 2,563 (26.8%) 5,051 (28.9%) 0.045  2,684 (28.2%) 4,927 (28.1%) 0.001 
   Glomerular disease 909 (9.5%) 1,936 (11.1%) 0.051  982 (10.3%) 1,829 (10.4%) 0.004 
   Other 1,059 (11.1%) 2,292 (13.1%) 0.062  1,162 (12.2%) 2,160 (12.3%) 0.004 
Body mass index          
   < 18.5 kg/m2 474 (5.0%) 844 (4.8%) 0.006  464 (4.9%) 854 (4.9%) 0.000 
   18.5 – 24.9 kg/m2 3,555 (37.2%) 6,285 (35.9%) 0.027  3,474 (36.4%) 6,371 (36.4%) 0.002 
   25.0 – 29.9 kg/m2 2,761 (28.9%) 4,978 (28.4%) 0.010  2,718 (28.5%) 5,005 (28.6%) 0.001 







History of prior renal 
transplant 
502 (5.3%) 1,204 (6.9%) 0.068  594 (6.2%) 1,103 (6.3%) 0.003 
Dialysis vintage        
   < 1.0 year 595 (6.2%) 935 (5.3%) 0.038  535 (5.6%) 987 (5.6%) 0.001 
   1.0 – 1.9 years 2,118 (22.2%) 3,705 (21.2%) 0.024  2,052 (21.5%) 3,778 (21.6%) 0.001 
   2.0 – 2.9 years 1,668 (17.5%) 2,778 (15.9%) 0.042  1,556 (16.3%) 2,875 (16.4%) 0.002 
   ≥ 3.0 years 5,177 (54.2%) 10,088 (57.6%) 0.070  5,388 (56.5%) 9,882 (56.4%) 0.003 
Atrial fibrillation 1,236 (12.9%) 2,525 (14.4%) 0.043  1,298 (13.6%) 2,425 (13.8%) 0.006 
Other arrhythmia 930 (9.7%) 1,630 (9.3%) 0.014  906 (9.5%) 1,657 (9.5%) 0.002 
Angina 210 (2.2%) 302 (1.7%) 0.034  180 (1.9%) 331 (1.9%) 0.000 
Cancer    312 (3.3%) 661 (3.8%) 0.028  182 (1.9%) 334 (1.9%) 0.000 
Conduction disorder 367 (3.8%) 496 (2.8%) 0.056  334 (3.5%) 626 (3.6%) 0.004 
COPD/asthma 1,704 (17.8%) 2,795 (16.0%) 0.050  304 (3.2%) 559 (3.2%) 0.000 
Coronary atherosclerosis 3,126 (32.7%) 4,960 (28.3%) 0.095  1,601 (16.8%) 2,923 (16.7%) 0.003 
Diabetes 5,473 (57.3%) 9,286 (53.0%) 0.085  2,867 (30.1%) 5,252 (30.0%) 0.002 
GI bleed    471 (4.9%) 932 (5.3%) 0.018  5,237 (54.9%) 9,587 (54.7%) 0.005 
Heart failure    4,107 (43.0%) 5,251 (30.0%) 0.272  503 (5.3%) 911 (5.2%) 0.004 
Hypertension 7,021 (73.5%) 12,652 (72.3%) 0.027  3,334 (35.0%) 6,089 (34.8%) 0.005 
Liver disease 421 (4.4%) 783 (4.5%) 0.003  434 (4.6%) 784 (4.5%) 0.004 
Myocardial infarction 642 (6.7%) 1,151 (6.6%) 0.006  644 (6.8%) 1,171 (6.7%) 0.003 
Peripheral artery disease 2,149 (22.5%) 3,729 (21.3%) 0.029  2,096 (22.0%) 3,820 (21.8%) 0.004 
Stroke 975 (10.2%) 1,876 (10.7%) 0.017  1,030 (10.8%) 1,861 (10.6%) 0.006 
Valvular disease 904 (9.5%) 1,337 (7.6%) 0.065  795 (8.3%) 1,457 (8.3%) 0.001 
History of non-complianceb 594 (6.2%) 1,021 (5.8%) 0.016  580 (6.1%) 1,051 (6.0%) 0.004 
Vascular access        
   Fistula 5,645 (59.1%) 10,054 (57.4%) 0.033  5,514 (57.8%) 10,150 (57.9%) 0.002 
   Graft 2,428 (25.4%) 4,451 (25.4%) 0.001  2,447 (25.7%) 4,470 (25.5%) 0.004 
   Catheter 1,485 (15.5%) 3,001 (17.1%) 0.043  1,571 (16.5%) 2,903 (16.6%) 0.002 
Interdialytic weight gain  
≥ 3 kg   








Delivered dialysis treatment 
time < 240 min 
7,657 (80.1%) 13,940 (79.6%) 0.012  7,626 (80.0%) 13,990 (79.8%) 0.004 
Pre-dialysis systolic BP        
   < 130 mmHg  1,384 (14.5%) 2,159 (12.3%) 0.063  1,241 (13.0%) 2,290 (13.1%) 0.001 
   130 – 149 mmHg 2,696 (28.2%) 4,744 (27.1%) 0.025  2,620 (27.5%) 4,809 (27.4%) 0.001 
   150 – 169 mmHg 3,175 (33.2%) 6,084 (34.8%) 0.032  3,251 (34.1%) 5,996 (34.2%) 0.002 
   ≥170 mmHg 2,303 (24.1%) 4,519 (25.8%) 0.040  2,419 (25.4%) 4,428 (25.3%) 0.003 
Recent history of intradialytic 
hypotensionc 
1,349 (14.1%) 2,363 (13.5%) 0.018  1,322 (13.9%) 2,415 (13.8%) 0.002 
Albumin           
   ≤ 3.0 g/dL 468 (4.9%) 883 (5.0%) 0.007  483 (5.1%) 877 (5.0%) 0.003 
   3.1 – 4.0 g/dL   6,221 (65.1%) 11,057 (63.2%) 0.040  6,091 (63.9%) 11,192 (63.9%) 0.001 
   > 4.0 g/dL 2,869 (30.0%) 5,566 (31.8%) 0.038  2,958 (31.0%) 5,453 (31.1%) 0.002 
Calcium            
   < 8.5 mg/dL 1,338 (14.0%) 2,497 (14.3%) 0.008  1,352 (14.2%) 2,488 (14.2%) 0.000 
   8.5 – 10.2 mg/dL 7,756 (81.1%) 14,159 (80.9%) 0.007  7,712 (80.9%) 14,181 (80.9%) 0.000 
   > 10.2 mg/dL 464 (4.9%) 850 (4.9%) 0.000  467 (4.9%) 853 (4.9%) 0.001 
Phosphorus        
   < 3.5 mg/dL 1,088 (11.4%) 1,907 (10.9%) 0.016  1,050 (11.0%) 1,936 (11.0%) 0.001 
   3.5 – 5.5 mg/dL 5,224 (54.7%) 9,431 (53.9%) 0.016  5,175 (54.3%) 9,497 (54.2%) 0.002 
   > 5.5 mg/dL 3,246 (34.0%) 6,168 (35.2%) 0.027  3,307 (34.7%) 6,090 (34.8%) 0.001 
Potassium        
   < 4.0 mEq/L 1,064 (11.1%) 1,918 (11.0%) 0.006  1,047 (11.0%) 1,931 (11.0%) 0.001 
   4.0 – 6.0 mEq/L 8,152 (85.3%) 14,915 (85.2%) 0.003  8,124 (85.2%) 14,935 (85.2%) 0.000 
   > 6.0 mEq/L 342 (3.6%) 673 (3.8%) 0.014  360 (3.8%) 656 (3.7%) 0.002 
Hemoglobin           
   < 9.5 g/dL 663 (6.9%) 1,166 (6.7%) 0.011  651 (6.8%) 1,186 (6.8%) 0.003 
   9.5 – 12.0 mg/dL 6,164 (64.5%) 10,709 (61.2%) 0.069  5,970 (62.6%) 10,943 (62.4%) 0.004 
   > 12.0 mg/dL 2,731 (28.6%) 5,631 (32.2%) 0.078  2,911 (30.5%) 5,394 (30.8%) 0.005 
Equilibrated Kt/V < 1.2 2,235 (23.4%) 3,850 (22.0%) 0.033  2,145 (22.5%) 3,943 (22.5%) 0.000 
Number of medications in last 
30 days of baseline 
5.5 ± 3.8 5.5 ± 3.9 0.014  5.5 ± 3.9 5.5 ± 3.9 0.014 








ACE inhibitor 2,232 (23.4%) 4,040 (23.1%) 0.006  2,223 (23.3%) 4,070 (23.2%) 0.002 
Angiotensin receptor blocker 1,212 (12.7%) 1,848 (10.6%) 0.066  1,102 (11.6%) 2,003 (11.4%) 0.004 
Calcium channel blocker 3,060 (32.0%) 5,959 (34.0%) 0.043  3,193 (33.5%) 5,853 (33.4%) 0.002 
Central alpha agonist 1,272 (13.3%) 2,486 (14.2%) 0.026  1,338 (14.0%) 2,446 (14.0%) 0.002 
Diuretic 1,239 (13.0%) 1,845 (10.5%) 0.075  1,095 (11.5%) 2,010 (11.5%) 0.001 
Vasodilator 997 (10.4%) 1,916 (10.9%) 0.017  1,030 (10.8%) 1,894 (10.8%) 0.000 
Statin 2,578 (27.0%) 4,509 (25.8%) 0.028  2,513 (26.4%) 4,607 (26.3%) 0.002 
Other cholesterol medicationd 394 (4.1%) 717 (4.1%) 0.001  393 (4.1%) 720 (4.1%) 0.001 
Digoxin 258 (2.7%) 332 (1.9%) 0.054  206 (2.2%) 382 (2.2%) 0.002 
Long-acting nitrate 845 (8.8%) 1,216 (6.9%) 0.070  733 (7.7%) 1,345 (7.7%) 0.000 
Antiplatelet medication 1,280 (13.4%) 2,065 (11.8%) 0.048  1,202 (12.6%) 2,188 (12.5%) 0.004 
Anticoagulant medication 711 (7.4%) 1,458 (8.3%) 0.033  754 (7.9%) 1,401 (8.0%) 0.003 
Midodrine 192 (2.0%) 350 (2.0%) 0.001  192 (2.0%) 352 (2.0%) 0.000 
Use of ≥ 1 potent inhibitor of 
CYP2D6e 
2,690 (29.5%) 5,162 (28.1%) 0.030  2,766 (29.0%) 5,090 (29.0%) 0.001 
All-covariates were measured during the baseline period prior to carvedilol or metoprolol initiation. Values for categorical variables are given as number (%) and 
as mean ± standard deviation for continuous variables.  
 
a  A standardized difference > 0.1 represents meaningful imbalance between groups.80 
 
b Claims-based definition of non-compliance included ICD-9 discharge diagnosis codes V15.81 (personal history of noncompliance with medical treatment, 
presenting hazards to health) and V45.12 (noncompliance with renal dialysis). 
 
c Patients were considered as having a recent history of intradialytic hypotension if they had an intradialytic nadir systolic blood pressure < 90 mmHg in at least 
30% of outpatient hemodialysis treatments in the last 30 days of the baseline period.57 
 
d Other cholesterol medications included the following non-statin cholesterol medications: bile acid sequestrants, cholesterol absorption inhibitors, fibrates and 
niacin.  
 
e Both carvedilol and metoprolol are metabolized by cytochrome P450 2D6. Concomitant use of medications that are potent inhibitors cytochrome P450 2D6 of 
may increase serum concentrations of both carvedilol and metoprolol, putting patients at increased risk for beta blocker—related adverse events such as 
hypotension. Cytochrome P450 2D6 inhibitors included: amiodarone, bupropion, chloroquine, cinacalcet, diphenhydramine, fluoxetine, haloperidol, imatinib, 
paroxetine, propafenone, propoxyphene, quinidine, terbinafine and thioridazine.  
 
Abbreviations: ACE, angiotensin converting enzyme; BP, blood pressure; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; GI, 











Table 6.3 Association between carvedilol versus metoprolol initiation and 1-year mortality among clinically relevant 
subgroups: intent-to-treat analysisa 
Patients with hypertension (n = 19,673) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol  12,652 2,273 (18.0%) 234.7 1.00 (ref.) 1.00 (ref.)  975 (7.7%) 100.7 1.00 (ref.) 1.00 (ref.) 
Carvedilol 7,021 1,401 (20.0%) 266.0 1.13 (1.06, 1.21) 1.09 (1.02, 1.17)  664 (9.5%) 126.1 1.25 (1.13, 1.38) 1.20 (1.09, 1.32) 
Patients with atrial fibrillation (n = 3,761) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol  2,525 707 (28.0%) 406.1 1.00 (ref.) 1.00 (ref.)  303 (12.0 %) 174.1 1.00 (ref.) 1.00 (ref.) 
Carvedilol 1,263 378 (30.6%) 458.4 1.13 (0.99, 1.23) 1.08 (0.94, 1.23)  178 (14.4 %) 215.9 1.23 (1.02, 1.48) 1.12 (0.93, 1.35) 
Patients with heart failure (n = 9,358) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol  5,251 1,280 (24.4%) 336.7 1.00 (ref.) 1.00 (ref.)  551 (10.5%) 144.9 1.00 (ref.) 1.00 (ref.) 
Carvedilol 4,107 995 (24.2%) 335.8 1.00 (0.92, 1.08) 1.03 (0.94, 1.12)  467 (11.4%) 157.6 1.09 (0.97, 1.24) 1.12 (0.99, 1.27) 
Patients with a recent myocardial infarction (n = 1,793) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol  1,151 315 (27.4%) 395.6 1.00 (ref.) 1.00 (ref.)  149 (12.9%) 187.1 1.00 (ref.) 1.00 (ref.) 
Carvedilol 642 194 (30.2%) 443.6 1.12 (0.94, 1.43) 1.04 (0.86, 1.26)  107 (16.7%) 244.7 1.31 (1.02, 1.68) 1.23 (0.96, 1.58) 
An intent-to-treat design was employed in all analyses. 
 
a Patient counts, event counts (% of patients) and event rates presented are based on the unweighted cohort. 
 
b Cox proportional hazards models were used to estimate the associations between carvedilol (versus metoprolol) initiation and 1-year all-cause mortality. 
 
c Fine and Gray proportional subdistribution hazards models were used to estimate the associations between carvedilol (versus metoprolol) initiation and 1-year 
cardiovascular mortality. Non-cardiovascular death was treated as a competing risk. 
 
d Adjusted analyses controlled for all variables listed in Table 6.2 using inverse probability of treatment weighting. Subgroups of interest were excluded the 
corresponding propensity score models. For example, in subgroup analyses of patients with hypertension, the hypertension covariate was excluded from the 
propensity score model. 
 








Table 6.4 Association between initiation of carvedilol versus initiation of the different metoprolol formulations and 1-
year mortality: intent-to-treat analysisa 
Carvedilol versus metoprolol tartrate (n = 21,294) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol tartrate 11,736 1,863 (15.9%) 205.6 1.00 (ref.) 1.00 (ref.)  797 (6.8%) 87.9 1.00 (ref.) 1.00 (ref.) 
Carvedilol 9,558 1,625 (17.0%) 225.1 1.09 (1.02, 1.17) 1.07 (0.99, 1.14)  782 (8.2%) 108.3 1.23 (1.11, 1.36) 1.20 (1.09, 1.32) 
Carvedilol versus metoprolol succinate (n = 15,328) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol succinate 5,770 808 (14.0%) 176.3 1.00 (ref.) 1.00 (ref.)  364 (6.3%) 79.4 1.00 (ref.) 1.00 (ref.) 
Carvedilol 9,558 1,625 (17.0%) 225.1 1.27 (1.17, 1.39) 1.10 (1.00, 1.22)  782 (8.2%) 108.3 1.34 (1.19, 1.52) 1.15 (1.02, 1.30) 
An intent-to-treat design was employed in all analyses. 
 
a Patient counts, event counts (% of patients) and event rates presented are from the unweighted cohort. 
 
b Cox proportional hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 1-year all-cause mortality; 
and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. 
 
c Fine and Gray proportional subdistribution hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 
1-year all-cause mortality; and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. Non-cardiovascular death was treated as a 
competing risk. 
 
d Adjusted analyses controlled for all variables listed in Table 6.2 using inverse probability of treatment weighting.  
 















Table 6.5 Association between low-dose carvedilol versus low-dose metoprolol initiation and 1-year mortality: intent-to-
treat analysisa 
Patients initiating a low-dose study beta blocker (n =22,362) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol 15,028 2,441 (16.0%) 206.7 1.00 (ref.) 1.00 (ref.)  1,048 (7.0%) 89.8 1.00 (ref.) 1.00 (ref.) 
Carvedilol 7,334 1,358 (18.5%) 246.8 1.19 (1.12, 1.28) 1.09 (1.02, 1.17)  6265 (9.1%) 120.9 1.33 (1.21, 1.47) 1.21 (1.10, 1.33) 
An intent-to-treat design was employed in all analyses. Low dose carvedilol was defined as a total daily dose of ≤ 25 mg/day. Low dose metoprolol was defined 
as a total daily dose of ≤100 mg/day. 
 
a Patient counts, event counts (% of patients) and event rates presented are from the unweighted cohort. 
 
b Cox proportional hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 1-year all-cause mortality; 
and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. 
 
c Fine and Gray proportional subdistribution hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 
1-year all-cause mortality; and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. Non-cardiovascular death was treated as a 
competing risk. 
 
d Adjusted analyses controlled for all variables listed in Table 6.2 using inverse probability of treatment weighting.  
 



























Table 6.6 Association between carvedilol versus metoprolol initiation and 1-year mortality among patients with the low-
income subsidy benefit: intent-to-treat analysisa 
Patients with the low-income subsidy benefit (n = 20,783) 
  1-year all-cause mortalityb  1-year cardiovascular mortalityc 






HR (95% CI) 
Adjusted 
HR (95% CI)d 





HR (95% CI) 
Adjusted 
HR (95% CI)d 
Metoprolol 13,524 1,937 (14.3%) 181.5 1.00 (ref.) 1.00 (ref.)  841 (6.2%) 78.8 1.00 (ref.) 1.00 (ref.) 
Carvedilol 7,259 1,162 (16.0%) 209.8 1.15 (1.07, 1.24) 1.10 (1.02, 1.19)  567 (7.8%) 102.4 1.29 (1.16, 1.44) 1.23 (1.10, 1.36) 
An intent-to-treat design was employed in all analyses.  
 
a Patient counts, event counts (% of patients) and event rates presented are from the unweighted cohort. 
 
b Cox proportional hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 1-year all-cause mortality; 
and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. 
 
c Fine and Gray proportional subdistribution hazards models were used to estimate the associations between: 1) carvedilol versus metoprolol tartrate initiation and 
1-year all-cause mortality; and 2) carvedilol versus metoprolol succinate initiation and 1-year all-cause mortality. Non-cardiovascular death was treated as a 
competing risk. 
 
d Adjusted analyses controlled for all variables listed in Table 6.2 using inverse probability of treatment weighting.  
 






Figure 6.1 Aim 3 study design 
 
 
Carvedilol and metoprolol initiators were defined as hemodialysis patients who had no record of a beta blocker 
prescription in the previous 180 days (beta blocker washout period). Among these patients, the index date was defined 
as the date of carvedilol or metoprolol initiation. Baseline covariates were identified in the 180-day period prior to the 
index date. Study follow-up began immediately after the index date. 
 



























Figure 6.3 Propensity score distribution of patients treated with carvedilol and metoprolol 
 
 
The blue solid line represents the propensity score distribution among metoprolol initiators. The red dashed line 

















Figure 6.4 Association between carvedilol versus metoprolol initiation and 1-year 





An intent-to-treat design was employed in all analyses. Cox proportional hazards models were used to estimate the 
association between carvedilol (versus metoprolol) initiation and 1-year all-cause mortality. Fine and Gray 
proportional subdistribution hazards models were used to estimate the association between carvedilol (versus 
metoprolol) initiation and 1-year cardiovascular mortality. In cardiovascular mortality analyses, non-cardiovascular 
death was treated as a competing risk. Inverse probability of treatment weighting was used in adjusted analyses to 
control for all the baseline covariates variables listed in Table 6.2. 
 





CHAPTER 7: CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS 
Aim 1: Patterns of beta blocker use 
 While this patterns of use study was conducted to inform Aims 2 and 3 of this dissertation, 
it does have broader implications. In a cohort of maintenance hemodialysis patients, we 
demonstrated that the utilization of beta blocker medications after index therapy initiation was 
dynamic. Both discontinuation and therapy re-initiation were common. When tracking beta 
blocker utilization post-index date with pharmacy claims data, making the assumption that patients 
continued beta blocker therapy during hospital and skilled nursing facility admissions resulted in 
lower estimated rates of beta blocker discontinuation as compared to rates of discontinuation based 
upon prescription fill information alone, regardless of the grace period used to define 
discontinuation. These findings suggest that administrative claims-based studies assessing the 
patterns of use of chronic disease medications, such as beta blocker therapy, in the hemodialysis 
population should consider accounting for hospital and skilled nursing facility admissions when 
assessing chronic disease medication use longitudinally.  
 
Aim 2: Beta blocker adherence and mortality  
Typically, PDC is calculated using pharmacy claims data by adding the number of days 
that a patient has prescription medication available to them (based on the date a prescription was 
dispensed and its days supply) during a set period of observation, divided by the number of days 
in the observation period. This standard approach for calculating PDC approach ignores time 




disease medications, such as beta blockers, are often provided to patients by hospital inpatient or 
skilled nursing facility pharmacies. During these admissions, prescription insurance-based home 
medication supplies are not utilized. Thus, in populations with high rates of hospital and skilled 
nursing facility admissions (e.g. hemodialysis patients), the standard PDC metric may misestimate 
the time patients have chronic disease medications available to them. In this dissertation aim, we 
found that the proportion of patients considered adherent to beta blocker therapy (PDC ≥ 80%) 
was lower when the standard PDC metric was employed as compared to a modified PDC metric 
that accounted for time spent in the hospital or skilled nursing facility. These results indicate that 
the classification of patients into adherent and non-adherent categories varies depending on the 
PDC metric used.  Furthermore, we found that patients who were adherent to beta blocker therapy 
(PDC ≥ 80%) as compared to those who were non-adherent (PDC < 80%) had lower rates of all-
cause mortality, regardless of the PDC metric used. However, notably, when modified (versus 
standard) beta blocker PDC was used to determine beta blocker adherence the observed 
adherence—mortality association was attenuated. 
Our results suggest that it may be important to consider time periods spent in the hospital 
or a skilled nursing facility when PDC metrics are used to evaluate the study medication 
adherence—mortality associations, especially in populations that experience high rates of the 
aforementioned admission types (e.g. hemodialysis patients). Further research evaluating the 
impact of the adherence adjustment method used in this dissertation is warranted.   
Aim 3: Comparative study of carvedilol versus metoprolol initiation and mortality 
To our knowledge, this dissertation aim was the first investigation evaluating the 
comparative mortality risk of carvedilol and metoprolol therapy among individuals receiving 




associated with increased 1-year all-cause and cardiovascular mortality. The observed associations 
were consistent within clinically relevant subgroups and robust across several sensitivity analyses. 
Data from our post hoc analysis indicate that one potential mechanism for the observed mortality 
associations may be an increased rate of intradialytic hypotension after carvedilol (versus 
metoprolol) initiation. Our results suggest that clinicians should consider potential adverse 
hemodynamic effects of carvedilol (versus metoprolol) when selecting between these beta blockers 
in hemodialysis patients.  It may be reasonable to consider metoprolol initiation (over carvedilol) 
among individuals at high risk for intradialytic hypotension. Alternatively, it may be prudent to 
recommend that patients hold carvedilol doses prior to hemodialysis in order to minimize its 
intradialytic hypotensive effects. Given the unique pharmacokinetic and hemodynamic 
considerations in the ESRD population, additional study of the efficacy and safety of beta blockers, 
as well as other cardioprotective medications with antihypertensive properties is needed. 
More broadly speaking, the results of this dissertation aim illustrates the importance of 
evaluating the safety and effectiveness of medications among hemodialysis patients, a special 
population with unique drug dosing considerations. In the absence of clinical trial data, large-scale, 
comparative effectiveness/safety studies will be needed to provide critical evidence to guide 
medication prescribing in ESRD. Furthermore, based on our findings and the results of other 
observational studies,46 dialytic medication clearance appears to be an important consideration 
when evaluating the risk-benefit profiles of medications in the hemodialysis population. While 
resources describing the extent of medication dialyzablity are available to the nephrology 
community,92, 93 the information contained in these references is dated. Available hemodialysis-
based pharmacokinetic data is often derived from studies conducted in an era prior to the 




there is a lack of available data describing the effect of renal replacement therapy on drug 
disposition under the dialysis treatment conditions of contemporary clinical practice. Thus, 
additional research aimed at determining the dialyzablity of medications commonly used by 





APPENDIX: SUPPLEMENTAL MATERIAL 
Supplemental Table 1. Baseline covariate definitions used in Aims 1, 2 and 3 
DEMOGRAPHICS AND PATIENT CHARACTERISTICS 
Covariate Description and definition Data source 
Age Age in years at the start of the baseline period USRDS Patients 






















Low-income subsidy Patient has Medicare Part D low-income subsidy 






USRDS Medicare Part D 
Year of index beta blocker was 
prescribed 
Calendar year in which index beta blocker 










USRDS Medicare Part D 
Cause of end-stage renal 
disease (ESRD) 








USRDS Medical Evidence 
Form 
Body mass index Body mass index determined using:  
1) last non-missing height during the baseline 
period; and 2) average post-dialysis weight during 
the last 30 days of the baseline period 
 
Computed as: weight in kg/(height in meters)2 
Large Dialysis Organization 
(LDO) Treatment (weight) 






Underweight -- BMI <18.5 kg/m2 
Normal -- BMI of 18.50 to <25 kg/m2 (ref.) 
Overweight -- BMI of 25 to <30 kg/m2 
Obese -- BMI ≥30 kg/m2 
 
History of ≥1 renal transplant History of at least 1 renal transplant (transplant 











< 1 year 
1 to 1.9 years (ref.) 
2 to 2.9 years 
≥3 years 
 
USRDS Medical Evidence 
Form 
COMORBID CONDITIONSa 
Covariate Description and definition Data source 
Atrial fibrillation Patient has atrial fibrillation? 
 






USRDS Part A/B claims 
Other arrhythmia Patient has other (non-atrial fibrillation) 
arrhythmias? 
 







USRDS Part A/B claims 
Angina Patient has angina? 
 






USRDS Part A/B claims 
Cancer Patient has a history of Cancer? 
 
ICD-9 diagnosis code(s): 140–149, 150–159, 
160–169, 170–176, 179–189, 190-199, 200–208, 










Conduction disorder Patient has a conduction disorder? 
 










Patient has COPD/asthma? 
 





USRDS Part A/B claims 
Coronary atherosclerosis Patient has coronary atherosclerosis? 
 






USRDS Part A/B claims 
Diabetes Patient has diabetes? 
 






USRDS Part A/B claims 
Gastrointestinal (GI) bleed Patient had a GI bleed? 
 
ICD-9 diagnosis code(s): 456.0–456.2, 530.7, 






USRDS Part A/B claims 
Heart failure Patient has heart failure? 
 







USRDS Part A/B claims 
Hypertension Patient has hypertension? 
 






USRDS Part A/B claims 
Liver disease Patient has liver disease (including hepatitis B, 
hepatitis C and chronic liver disease)? 
 
ICD-9 diagnosis code(s): 070.2–070.3, 070.41, 










Myocardial infarction Patient had a myocardial infarction? 
 






USRDS Part A/B claims 
Peripheral artery disease Patient has peripheral artery disease? 
 







USRDS Part A/B claims 
Stroke Patient has a history of stroke? 
 






USRDS Part A/B claims 
Valvular disease Patient has valvular disease? 
 






USRDS Part A/B claims 
History of non-compliance Patient has a history of non-compliance? 
 






USRDS Part A/B claims 
DIALYSIS TREATMENT 
Covariate Description and definition Data source 








LDO Treatment and Access 
files 
Interdialytic weight gain Average interdialytic weight gain in the last 30 
days of the baseline period 
 
Categories 
<3 kg (ref.) 
≥3 kg 
 




Delivered dialysis treatment 
time 
Average delivered treatment time in the last 30 




≥240 min (ref.) 
 
LDO Treatment file 
Pre-dialysis systolic blood 
pressure 
Average pre-dialysis systolic blood pressure 




130 – 149 mmHg (ref.) 
150 – 169 mmHg 
≥170 mmHg 
 
LDO Treatment file 
Recent history of intradialytic 
hypotension 
Had an intradialytic nadir systolic blood pressure 
<90 mmHg in at least 30% of dialysis treatments 






LDO Treatment file 
Recent history of intradialytic 
hypertension 
Had a pre- to post-dialysis systolic BP rise >0 
mmHg94 in at least 30% of dialysis treatments in 






LDO Treatment file 
LABORATORY 
Covariate Description and definition Data source 
Albumin Last non-missing albumin measurement during 





>4.0 g/dL (ref.) 
 
LDO Lab file 
Calcium Last non-missing corrected calcium measurement 




8.5 – 10.2 mg/dL (ref.) 
>10.2 mg/dL 
 
LDO Labs file 
Phosphorus Last non-missing serum phosphorus measurement 




3.5 – 5.5 mg/dL (ref.) 
>5.5 mg/dL 
 









4-6 mEq/L (ref.) 
>6 mEq/L 
 
LDO Labs file 








LDO Labs file 






LDO Labs file 
MEDICATION USE 
Covariate Description and definition Data source 
Number of baseline 
medications 
Number of prescription medications used in the 
last 30 days of the baseline period 
 
USRDS Medicare Part D 
claims 







USRDS Medicare Part D 
claims 
Angiotensin converting 
enzyme (ACE) inhibitor 







USRDS Medicare Part D 
Claims 
Angiotensin receptor blocker 
(ARB) 







USRDS Medicare Part D 
Claims 
Calcium channel blocker Use of a calcium channel blocker in the last 30 











Central alpha agonist Use of a central alpha agonist in the last 30 days 






USRDS Medicare Part D 
Claims 







USRDS Medicare Part D 
Claims 







USRDS Medicare Part D 
Claims 







USRDS Medicare Part D 
Claims 
Other cholesterol medication Use of another non-statin cholesterol medication 
(including bile acid sequestrants, cholesterol 
absorption inhibitors, fibrates or niacin) in the last 






USRDS Medicare Part D 
Claims 







USRDS Medicare Part D 
Claims 
Long-acting nitrate Use of a long-acting nitrate in the last 30 days of 






USRDS Medicare Part D 
Claims 
Antiplatelet Use of an antiplatelet medication in the last 30 





USRDS Medicare Part D 
Claims 
Anticoagulant Use of an anticoagulant medication in the last 30 
days of the baseline period? 
 
















USRDS Medicare Part D 
Claims 
Use of ≥1 potent inhibitor of 
CYP2D6 
Use of ≥1 medication that is a potent inhibitor of 
CYP2D6 (including amiodarone, bupropion, 
chloroquine, cinacalcet, diphenhydramine, 
fluoxetine, haloperidol, imatinib, paroxetine, 
propafenone, propoxyphene, quinidine, 
terbinafine or thioridazine) in the last 30 days of 






USRDS Medicare Part D 
Claims 
a Relevant administrative claims-based covariates were identified in the 180-day baseline period using USRDS data. 
For comorbidities specified in the table, each clinical condition of interest was identified using USRDS Medicare Part 
A and B claims. Comorbid conditions were considered present if an applicable ICD-9 discharge code (located in any 
position) was associated with at least one inpatient, home health, or skilled nursing facility claim during the 180-day 
baseline period; or if an applicable ICD-9 code (located in any position) was identified in ≥2 outpatient, 
physician/supplier or dialysis claims separated by at least 7 days during the 180-day baseline period. Specified three 
digit ICD-9 diagnosis categories include all existing 4th and 5th digit diagnosis codes. Specified four digit ICD-9 
diagnosis categories include all existing 5th digit diagnosis codes. 
 
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; COPD, chronic obstructive 
pulmonary disease; ESRD, end-stage renal disease; GI, gastrointestinal; ICD-9, International Classification of 
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